{"LRHnoXMAAAAJ": [["M Silverberg", 2020, "A221 CROHN\u2019S DISEASE POLYGENIC RISK SCORE IS ASSOCIATED WITH FECAL CALPROTECTIN CONCENTRATION IN ASYMPTOMATIC FIRST-DEGREE RELATIVES OF CROHN\u2019S DISEASE PATIENTS"], ["K Shestopaloff", 2020, "A221 CROHN\u2019S DISEASE POLYGENIC RISK SCORE IS ASSOCIATED WITH FECAL CALPROTECTIN CONCENTRATION IN ASYMPTOMATIC FIRST-DEGREE RELATIVES OF CROHN\u2019S DISEASE PATIENTS"], ["J Raygoza Garay", 2020, "A221 CROHN\u2019S DISEASE POLYGENIC RISK SCORE IS ASSOCIATED WITH FECAL CALPROTECTIN CONCENTRATION IN ASYMPTOMATIC FIRST-DEGREE RELATIVES OF CROHN\u2019S DISEASE PATIENTS"], ["S Lee", 2020, "A221 CROHN\u2019S DISEASE POLYGENIC RISK SCORE IS ASSOCIATED WITH FECAL CALPROTECTIN CONCENTRATION IN ASYMPTOMATIC FIRST-DEGREE RELATIVES OF CROHN\u2019S DISEASE PATIENTS"], ["W Xu", 2020, "A221 CROHN\u2019S DISEASE POLYGENIC RISK SCORE IS ASSOCIATED WITH FECAL CALPROTECTIN CONCENTRATION IN ASYMPTOMATIC FIRST-DEGREE RELATIVES OF CROHN\u2019S DISEASE PATIENTS"], ["N Power", 2020, "A221 CROHN\u2019S DISEASE POLYGENIC RISK SCORE IS ASSOCIATED WITH FECAL CALPROTECTIN CONCENTRATION IN ASYMPTOMATIC FIRST-DEGREE RELATIVES OF CROHN\u2019S DISEASE PATIENTS"], ["K Croitoru", 2020, "A221 CROHN\u2019S DISEASE POLYGENIC RISK SCORE IS ASSOCIATED WITH FECAL CALPROTECTIN CONCENTRATION IN ASYMPTOMATIC FIRST-DEGREE RELATIVES OF CROHN\u2019S DISEASE PATIENTS"], ["M Smith", 2020, "A221 CROHN\u2019S DISEASE POLYGENIC RISK SCORE IS ASSOCIATED WITH FECAL CALPROTECTIN CONCENTRATION IN ASYMPTOMATIC FIRST-DEGREE RELATIVES OF CROHN\u2019S DISEASE PATIENTS"], ["W Turpin", 2020, "A221 CROHN\u2019S DISEASE POLYGENIC RISK SCORE IS ASSOCIATED WITH FECAL CALPROTECTIN CONCENTRATION IN ASYMPTOMATIC FIRST-DEGREE RELATIVES OF CROHN\u2019S DISEASE PATIENTS"], ["AD Paterson", 2020, "A221 CROHN\u2019S DISEASE POLYGENIC RISK SCORE IS ASSOCIATED WITH FECAL CALPROTECTIN CONCENTRATION IN ASYMPTOMATIC FIRST-DEGREE RELATIVES OF CROHN\u2019S DISEASE PATIENTS"], ["O Espin-Garcia", 2020, "A221 CROHN\u2019S DISEASE POLYGENIC RISK SCORE IS ASSOCIATED WITH FECAL CALPROTECTIN CONCENTRATION IN ASYMPTOMATIC FIRST-DEGREE RELATIVES OF CROHN\u2019S DISEASE PATIENTS"], ["JR Conner", 2020, "A41 LOSS OF SATB2 EXPRESSION IN COLORECTAL CANCER IS ASSOCIATED WITH DURATION OF INFLAMMATORY BOWEL DISEASE"], ["K Borowski", 2020, "A41 LOSS OF SATB2 EXPRESSION IN COLORECTAL CANCER IS ASSOCIATED WITH DURATION OF INFLAMMATORY BOWEL DISEASE"], ["J Atin", 2020, "A41 LOSS OF SATB2 EXPRESSION IN COLORECTAL CANCER IS ASSOCIATED WITH DURATION OF INFLAMMATORY BOWEL DISEASE"], ["J Stempak", 2020, "A41 LOSS OF SATB2 EXPRESSION IN COLORECTAL CANCER IS ASSOCIATED WITH DURATION OF INFLAMMATORY BOWEL DISEASE"], ["C Hernandez-Rocha", 2020, "A41 LOSS OF SATB2 EXPRESSION IN COLORECTAL CANCER IS ASSOCIATED WITH DURATION OF INFLAMMATORY BOWEL DISEASE"], ["MS Silverberg", 2020, "A9 BACTERIAL BILE SALT HYDROLASE GENE ABUNDANCE IS ASSOCIATED WITH RORC GENE EXPRESSION IN INTESTINAL MUCOSA OF INFLAMMATORY DISEASE PATIENTS"], ["SI Stockhamer", 2020, "Dietary Guidance for Patients with Inflammatory Bowel Disease from the International Organization for the Study of Inflammatory Bowel Disease"], ["MT Abreu", 2020, "Dietary Guidance for Patients with Inflammatory Bowel Disease from the International Organization for the Study of Inflammatory Bowel Disease"], ["GL Trakman", 2020, "Dietary Guidance for Patients with Inflammatory Bowel Disease from the International Organization for the Study of Inflammatory Bowel Disease"], ["MA Kamm", 2020, "Dietary Guidance for Patients with Inflammatory Bowel Disease from the International Organization for the Study of Inflammatory Bowel Disease"], ["JD Lewis", 2020, "Dietary Guidance for Patients with Inflammatory Bowel Disease from the International Organization for the Study of Inflammatory Bowel Disease"], ["PR Gibson", 2020, "Dietary Guidance for Patients with Inflammatory Bowel Disease from the International Organization for the Study of Inflammatory Bowel Disease"], ["C Gasche", 2020, "Dietary Guidance for Patients with Inflammatory Bowel Disease from the International Organization for the Study of Inflammatory Bowel Disease"], ["E Wine", 2020, "Dietary Guidance for Patients with Inflammatory Bowel Disease from the International Organization for the Study of Inflammatory Bowel Disease"], ["LC Garces", 2020, "Dietary Guidance for Patients with Inflammatory Bowel Disease from the International Organization for the Study of Inflammatory Bowel Disease"], ["MB Hammami", 2020, "Dietary Guidance for Patients with Inflammatory Bowel Disease from the International Organization for the Study of Inflammatory Bowel Disease"], ["R Sigall Boneh", 2020, "Dietary Guidance for Patients with Inflammatory Bowel Disease from the International Organization for the Study of Inflammatory Bowel Disease"], ["IE Koutroubakis", 2020, "Dietary Guidance for Patients with Inflammatory Bowel Disease from the International Organization for the Study of Inflammatory Bowel Disease"], ["A Ananthakrishnan", 2020, "Dietary Guidance for Patients with Inflammatory Bowel Disease from the International Organization for the Study of Inflammatory Bowel Disease"], ["JO Lindsay", 2020, "Dietary Guidance for Patients with Inflammatory Bowel Disease from the International Organization for the Study of Inflammatory Bowel Disease"], ["OM Damas", 2020, "Dietary Guidance for Patients with Inflammatory Bowel Disease from the International Organization for the Study of Inflammatory Bowel Disease"], ["G Rogler", 2020, "Dietary Guidance for Patients with Inflammatory Bowel Disease from the International Organization for the Study of Inflammatory Bowel Disease"], ["McKeever Liam", 2020, "Dietary Guidance for Patients with Inflammatory Bowel Disease from the International Organization for the Study of Inflammatory Bowel Disease"], ["A Levine", 2020, "Dietary Guidance for Patients with Inflammatory Bowel Disease from the International Organization for the Study of Inflammatory Bowel Disease"], ["JM Rhodes", 2020, "Dietary Guidance for Patients with Inflammatory Bowel Disease from the International Organization for the Study of Inflammatory Bowel Disease"], ["G Syme", 2020, "Dietary Guidance for Patients with Inflammatory Bowel Disease from the International Organization for the Study of Inflammatory Bowel Disease"], ["U Mahadevan", 2020, "Dietary Guidance for Patients with Inflammatory Bowel Disease from the International Organization for the Study of Inflammatory Bowel Disease"], ["CK Yao", 2020, "Dietary Guidance for Patients with Inflammatory Bowel Disease from the International Organization for the Study of Inflammatory Bowel Disease"], ["K Boland", 2020, "A101 USTEKINUMAB LEVELS MEASURED DURING INDUCTION ARE ASSOCIATED WITH CLINICAL AND BIOCHEMICAL OUTCOMES AT WEEK 12 OF TREATMENT IN CROHN\u2019S DISEASE"], ["S Rho", 2020, "A101 USTEKINUMAB LEVELS MEASURED DURING INDUCTION ARE ASSOCIATED WITH CLINICAL AND BIOCHEMICAL OUTCOMES AT WEEK 12 OF TREATMENT IN CROHN\u2019S DISEASE"], ["M Walshe", 2020, "A101 USTEKINUMAB LEVELS MEASURED DURING INDUCTION ARE ASSOCIATED WITH CLINICAL AND BIOCHEMICAL OUTCOMES AT WEEK 12 OF TREATMENT IN CROHN\u2019S DISEASE"], ["Severine Vermeire", 2020, "Development and validation of a test to monitor endoscopic activity in patients with Crohn\u2019s disease based on serum levels of proteins"], ["Xiao-jun Li", 2020, "Development and validation of a test to monitor endoscopic activity in patients with Crohn\u2019s disease based on serum levels of proteins"], ["David Laharie", 2020, "Development and validation of a test to monitor endoscopic activity in patients with Crohn\u2019s disease based on serum levels of proteins"], ["Andres Yarur", 2020, "Development and validation of a test to monitor endoscopic activity in patients with Crohn\u2019s disease based on serum levels of proteins"], ["Edoardo Savarino", 2020, "Development and validation of a test to monitor endoscopic activity in patients with Crohn\u2019s disease based on serum levels of proteins"], ["Anjali Jain", 2020, "Development and validation of a test to monitor endoscopic activity in patients with Crohn\u2019s disease based on serum levels of proteins"], ["Lauren Okada", 2020, "Development and validation of a test to monitor endoscopic activity in patients with Crohn\u2019s disease based on serum levels of proteins"], ["Angelina Collins", 2020, "Development and validation of a test to monitor endoscopic activity in patients with Crohn\u2019s disease based on serum levels of proteins"], ["Mark S Silverberg", 2020, "Development and validation of a test to monitor endoscopic activity in patients with Crohn\u2019s disease based on serum levels of proteins"], ["Crystal Kuy", 2020, "Development and validation of a test to monitor endoscopic activity in patients with Crohn\u2019s disease based on serum levels of proteins"], ["Larry Mimms", 2020, "Development and validation of a test to monitor endoscopic activity in patients with Crohn\u2019s disease based on serum levels of proteins"], ["Orlaith Kelly", 2020, "Development and validation of a test to monitor endoscopic activity in patients with Crohn\u2019s disease based on serum levels of proteins"], ["Waqqas Afif", 2020, "Development and validation of a test to monitor endoscopic activity in patients with Crohn\u2019s disease based on serum levels of proteins"], ["Siddharth Singh", 2020, "Development and validation of a test to monitor endoscopic activity in patients with Crohn\u2019s disease based on serum levels of proteins"], ["Giorgia Bodini", 2020, "Development and validation of a test to monitor endoscopic activity in patients with Crohn\u2019s disease based on serum levels of proteins"], ["Parambir S Dulai", 2020, "Development and validation of a test to monitor endoscopic activity in patients with Crohn\u2019s disease based on serum levels of proteins"], ["Brigid S Boland", 2020, "Development and validation of a test to monitor endoscopic activity in patients with Crohn\u2019s disease based on serum levels of proteins"], ["Jessica Ho", 2020, "Development and validation of a test to monitor endoscopic activity in patients with Crohn\u2019s disease based on serum levels of proteins"], ["Edouard Louis", 2020, "Development and validation of a test to monitor endoscopic activity in patients with Crohn\u2019s disease based on serum levels of proteins"], ["Michael Hale", 2020, "Development and validation of a test to monitor endoscopic activity in patients with Crohn\u2019s disease based on serum levels of proteins"], ["William J Sandborn", 2020, "Development and validation of a test to monitor endoscopic activity in patients with Crohn\u2019s disease based on serum levels of proteins"], ["Geert D\u2019Haens", 2020, "Development and validation of a test to monitor endoscopic activity in patients with Crohn\u2019s disease based on serum levels of proteins"], ["Venkateswarlu Kondragunta", 2020, "Development and validation of a test to monitor endoscopic activity in patients with Crohn\u2019s disease based on serum levels of proteins"], ["Robert Battat", 2020, "Development and validation of a test to monitor endoscopic activity in patients with Crohn\u2019s disease based on serum levels of proteins"], ["Mark A Valasek", 2020, "Development and validation of a test to monitor endoscopic activity in patients with Crohn\u2019s disease based on serum levels of proteins"], ["Benjamin Huang", 2020, "Development and validation of a test to monitor endoscopic activity in patients with Crohn\u2019s disease based on serum levels of proteins"], ["Kurtis R Bray", 2020, "Development and validation of a test to monitor endoscopic activity in patients with Crohn\u2019s disease based on serum levels of proteins"], ["Kelly D Hester", 2020, "Development and validation of a test to monitor endoscopic activity in patients with Crohn\u2019s disease based on serum levels of proteins"], ["Sandra El-Hachem", 2020, "Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group"], ["Gerald Dryden", 2020, "Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group"], ["Taku Kobayashi", 2020, "Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group"], ["Yago Gonzalez Lama", 2020, "Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group"], ["Amandeep Shergill", 2020, "Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group"], ["Bego\u00f1a Gonz\u00e1lez Su\u00e1rez", 2020, "Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group"], ["David H Bruining", 2020, "Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group"], ["Paulo Gustavo Kotze", 2020, "Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group"], ["Raymond Cross", 2020, "Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group"], ["Bo Shen", 2020, "Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group"], ["Charles N Bernstein", 2020, "Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group"], ["Shou-Jiang Tang", 2020, "Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group"], ["Nayantara Coelho-Prabhu", 2020, "Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group"], ["Nan Lan", 2020, "Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group"], ["Shengyu Zhang", 2020, "Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group"], ["Gursimran Kochhar", 2020, "Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group"], ["Shyam Thakkar", 2020, "Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group"], ["Ravi P Kiran", 2020, "Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group"], ["Martin Bortlik", 2020, "Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group"], ["Milan Lukas", 2020, "Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group"], ["David A Schwartz", 2020, "Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group"], ["Udayakumar Navaneethan", 2020, "Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group"], ["Francis A Farraye", 2020, "Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group"], ["Marietta Iacucci", 2020, "Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group"], ["Ren Mao", 2020, "Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group"], ["Martin Lukas", 2020, "Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group"], ["Guodong Chen", 2020, "Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group"], ["Richard Kirsch", 2019, "Histological Markers of Clinical Relapse in Endoscopically Quiescent Ulcerative Colitis"], ["Callum Dargavel", 2019, "Histological Markers of Clinical Relapse in Endoscopically Quiescent Ulcerative Colitis"], ["Robert Riddell", 2019, "Histological Markers of Clinical Relapse in Endoscopically Quiescent Ulcerative Colitis"], ["Boyko Kabakchiev", 2019, "Histological Markers of Clinical Relapse in Endoscopically Quiescent Ulcerative Colitis"], ["David Kevans", 2019, "Histological Markers of Clinical Relapse in Endoscopically Quiescent Ulcerative Colitis"], ["Orlaith B Kelly", 2019, "Differential miRNA Expression in Ileal and Colonic Tissues Reveals an Altered Immunoregulatory Molecular Profile in Individuals With Crohn\u2019s Disease versus Healthy Subjects"], ["Aylia Mohammadi", 2019, "Differential miRNA Expression in Ileal and Colonic Tissues Reveals an Altered Immunoregulatory Molecular Profile in Individuals With Crohn\u2019s Disease versus Healthy Subjects"], ["Michelle I Smith", 2019, "Differential miRNA Expression in Ileal and Colonic Tissues Reveals an Altered Immunoregulatory Molecular Profile in Individuals With Crohn\u2019s Disease versus Healthy Subjects"], ["Karen Madsen", 2019, "Analysis of Genetic Association of Intestinal Permeability in Healthy First-degree Relatives of Patients with Crohn\u2019s Disease"], ["Anne M Griffiths", 2019, "Analysis of Genetic Association of Intestinal Permeability in Healthy First-degree Relatives of Patients with Crohn\u2019s Disease"], ["Osvaldo Espin-Garcia", 2019, "Analysis of Genetic Association of Intestinal Permeability in Healthy First-degree Relatives of Patients with Crohn\u2019s Disease"], ["Ernest G Seidman", 2019, "Analysis of Genetic Association of Intestinal Permeability in Healthy First-degree Relatives of Patients with Crohn\u2019s Disease"], ["Kenneth Croitoru", 2019, "Analysis of Genetic Association of Intestinal Permeability in Healthy First-degree Relatives of Patients with Crohn\u2019s Disease"], ["Larbi Bedrani", 2019, "Analysis of Genetic Association of Intestinal Permeability in Healthy First-degree Relatives of Patients with Crohn\u2019s Disease"], ["Andrew D Paterson", 2019, "Analysis of Genetic Association of Intestinal Permeability in Healthy First-degree Relatives of Patients with Crohn\u2019s Disease"], ["Wei Xu", 2019, "Analysis of Genetic Association of Intestinal Permeability in Healthy First-degree Relatives of Patients with Crohn\u2019s Disease"], ["Paul Moayyedi", 2019, "Analysis of Genetic Association of Intestinal Permeability in Healthy First-degree Relatives of Patients with Crohn\u2019s Disease"], ["David Mack", 2019, "Analysis of Genetic Association of Intestinal Permeability in Healthy First-degree Relatives of Patients with Crohn\u2019s Disease"], ["Mark Ropeleski", 2019, "Analysis of Genetic Association of Intestinal Permeability in Healthy First-degree Relatives of Patients with Crohn\u2019s Disease"], ["Williams Turpin", 2019, "Analysis of Genetic Association of Intestinal Permeability in Healthy First-degree Relatives of Patients with Crohn\u2019s Disease"], ["Kevan Jacobson", 2019, "Analysis of Genetic Association of Intestinal Permeability in Healthy First-degree Relatives of Patients with Crohn\u2019s Disease"], ["John K Marshall", 2019, "Analysis of Genetic Association of Intestinal Permeability in Healthy First-degree Relatives of Patients with Crohn\u2019s Disease"], ["Dan Turner", 2019, "Analysis of Genetic Association of Intestinal Permeability in Healthy First-degree Relatives of Patients with Crohn\u2019s Disease"], ["Thomas Walters", 2019, "Analysis of Genetic Association of Intestinal Permeability in Healthy First-degree Relatives of Patients with Crohn\u2019s Disease"], ["Juan Antonio Raygoza Garay", 2019, "Analysis of Genetic Association of Intestinal Permeability in Healthy First-degree Relatives of Patients with Crohn\u2019s Disease"], ["Jonathan B Meddings", 2019, "Analysis of Genetic Association of Intestinal Permeability in Healthy First-degree Relatives of Patients with Crohn\u2019s Disease"], ["Brian G Feagan", 2019, "Analysis of Genetic Association of Intestinal Permeability in Healthy First-degree Relatives of Patients with Crohn\u2019s Disease"], ["Sara Rahmati", 2019, "The Cutaneous Microbiome of Psoriatic Disease Is Influenced by Disease Susceptibility HLA Alleles but Not Clinical Phenotype"], ["Justine Ye", 2019, "The Cutaneous Microbiome of Psoriatic Disease Is Influenced by Disease Susceptibility HLA Alleles but Not Clinical Phenotype"], ["Mark Silverberg", 2019, "The Cutaneous Microbiome of Psoriatic Disease Is Influenced by Disease Susceptibility HLA Alleles but Not Clinical Phenotype"], ["Vinod Chandran", 2019, "The Cutaneous Microbiome of Psoriatic Disease Is Influenced by Disease Susceptibility HLA Alleles but Not Clinical Phenotype"], ["Meital Yerushalmi", 2019, "The Cutaneous Microbiome of Psoriatic Disease Is Influenced by Disease Susceptibility HLA Alleles but Not Clinical Phenotype"], ["Lihi Eder", 2019, "The Cutaneous Microbiome of Psoriatic Disease Is Influenced by Disease Susceptibility HLA Alleles but Not Clinical Phenotype"], ["Remy Pollock", 2019, "The Cutaneous Microbiome of Psoriatic Disease Is Influenced by Disease Susceptibility HLA Alleles but Not Clinical Phenotype"], ["Ofer Ben\u2010Bassat", 2019, "Associations between quantitative evaluation of bowel wall microvascular flow by contrast\u2010enhanced ultrasound and indices of disease activity in Crohn's disease patients using \u2026"], ["Mostafa Atri", 2019, "Associations between quantitative evaluation of bowel wall microvascular flow by contrast\u2010enhanced ultrasound and indices of disease activity in Crohn's disease patients using \u2026"], ["Amin Nazarian", 2019, "Associations between quantitative evaluation of bowel wall microvascular flow by contrast\u2010enhanced ultrasound and indices of disease activity in Crohn's disease patients using \u2026"], ["John Hudson", 2019, "Associations between quantitative evaluation of bowel wall microvascular flow by contrast\u2010enhanced ultrasound and indices of disease activity in Crohn's disease patients using \u2026"], ["Shadman Islam", 2019, "Associations between quantitative evaluation of bowel wall microvascular flow by contrast\u2010enhanced ultrasound and indices of disease activity in Crohn's disease patients using \u2026"], ["Hillary A Steinhart", 2019, "Associations between quantitative evaluation of bowel wall microvascular flow by contrast\u2010enhanced ultrasound and indices of disease activity in Crohn's disease patients using \u2026"], ["Petros Zezos", 2019, "Associations between quantitative evaluation of bowel wall microvascular flow by contrast\u2010enhanced ultrasound and indices of disease activity in Crohn's disease patients using \u2026"], ["Eran Zittan", 2019, "Associations between quantitative evaluation of bowel wall microvascular flow by contrast\u2010enhanced ultrasound and indices of disease activity in Crohn's disease patients using \u2026"], ["Karen Boland", 2019, "Identification of Target Golimumab Levels in Maintenance Therapy of Crohn\u2019s Disease and Ulcerative Colitis Associated With Mucosal Healing"], ["Joanne Stempak", 2019, "Identification of Target Golimumab Levels in Maintenance Therapy of Crohn\u2019s Disease and Ulcerative Colitis Associated With Mucosal Healing"], ["Tomer Greener", 2019, "Identification of Target Golimumab Levels in Maintenance Therapy of Crohn\u2019s Disease and Ulcerative Colitis Associated With Mucosal Healing"], ["Joelle Soriano", 2019, "Identification of Target Golimumab Levels in Maintenance Therapy of Crohn\u2019s Disease and Ulcerative Colitis Associated With Mucosal Healing"], ["A Hillary Steinhart", 2019, "Identification of Target Golimumab Levels in Maintenance Therapy of Crohn\u2019s Disease and Ulcerative Colitis Associated With Mucosal Healing"], ["Jenna Tessolini", 2019, "Identification of Target Golimumab Levels in Maintenance Therapy of Crohn\u2019s Disease and Ulcerative Colitis Associated With Mucosal Healing"], ["Adam V Weizman", 2019, "Identification of Target Golimumab Levels in Maintenance Therapy of Crohn\u2019s Disease and Ulcerative Colitis Associated With Mucosal Healing"], ["Geoffrey Nguyen", 2019, "Identification of Target Golimumab Levels in Maintenance Therapy of Crohn\u2019s Disease and Ulcerative Colitis Associated With Mucosal Healing"], ["Rachelle Li", 2019, "Identification of Target Golimumab Levels in Maintenance Therapy of Crohn\u2019s Disease and Ulcerative Colitis Associated With Mucosal Healing"], ["Krzysztof Borowski", 2019, "The Unsolved Link of Genetic Markers and Crohn\u2019s Disease Progression: A North American Cohort Experience"], ["Deepah Panikkath", 2019, "The Unsolved Link of Genetic Markers and Crohn\u2019s Disease Progression: A North American Cohort Experience"], ["Sarah O\u2019Donnell", 2019, "The Unsolved Link of Genetic Markers and Crohn\u2019s Disease Progression: A North American Cohort Experience"], ["Raquel Milgrom", 2019, "The Unsolved Link of Genetic Markers and Crohn\u2019s Disease Progression: A North American Cohort Experience"], ["Bertus Eksteen", 2019, "The Unsolved Link of Genetic Markers and Crohn\u2019s Disease Progression: A North American Cohort Experience"], ["Gilaad G Kaplan", 2019, "The Unsolved Link of Genetic Markers and Crohn\u2019s Disease Progression: A North American Cohort Experience"], ["Dermot PB McGovern", 2019, "The Unsolved Link of Genetic Markers and Crohn\u2019s Disease Progression: A North American Cohort Experience"], ["Benjamin M Neale", 2019, "Correction: insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population"], ["International IBD Genetics Consortium", 2019, "Correction: insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population"], ["Monkol Lek", 2019, "Correction: insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population"], ["Judy H Cho", 2019, "Correction: insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population"], ["Nikolas Pontikos", 2019, "Correction: insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population"], ["Laurent Beaugerie", 2019, "Correction: insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population"], ["Konrad J Karczewski", 2019, "Correction: insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population"], ["Gil Atzmon", 2019, "Correction: insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population"], ["Daniel Graham", 2019, "Correction: insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population"], ["Nir Barzilai", 2019, "Correction: insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population"], ["Chaim Jalas", 2019, "Correction: insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population"], ["Paivi Saavalainen", 2019, "Correction: insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population"], ["Benjamin Glaser", 2019, "Correction: insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population"], ["Andrea Ganna", 2019, "Correction: insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population"], ["Ben Weisburd", 2019, "Correction: insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population"], ["Ann Pulver", 2019, "Correction: insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population"], ["Brandon E Avila", 2019, "Correction: insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population"], ["Mitja Kurki", 2019, "Correction: insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population"], ["Philippe Seksik", 2019, "Correction: insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population"], ["Steven R Brant", 2019, "Correction: insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population"], ["Anthony W Segal", 2019, "Correction: insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population"], ["Talin Haritunians", 2019, "Correction: insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population"], ["Johannes Bethge", 2019, "Correction: insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population"], ["Manuel A Rivas", 2019, "Correction: insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population"], ["Eric V Minikel", 2019, "Correction: insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population"], ["T2D-GENES Consortium", 2019, "Correction: insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population"], ["Martti Farkkila", 2019, "Correction: insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population"], ["Bernd Bokemeyer", 2019, "Correction: insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population"], ["Jonathan Bloom", 2019, "Correction: insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population"], ["Aarno Palotie", 2019, "Correction: insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population"], ["Carl A Anderson", 2019, "Correction: insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population"], ["Jeffrey C Barrett", 2019, "Correction: insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population"], ["Christine Stevens", 2019, "Correction: insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population"], ["Vincent Plagnol", 2019, "Correction: insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population"], ["Daniel G MacArthur", 2019, "Correction: insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population"], ["NIDDK IBD Genetics Consortium", 2019, "Correction: insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population"], ["Adam P Levine", 2019, "Correction: insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population"], ["Graham Heap", 2019, "Correction: insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population"], ["Harry Sokol", 2019, "Correction: insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population"], ["Matti Pirinen", 2019, "Correction: insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population"], ["Inga Peter", 2019, "Correction: insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population"], ["Britt-Sabina Petersen", 2019, "Correction: insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population"], ["Stefan Schreiber", 2019, "Correction: insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population"], ["Stephan Targan", 2019, "Correction: insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population"], ["Hailiang Huang", 2019, "Correction: insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population"], ["Ramnik J Xavier", 2019, "Correction: insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population"], ["John D Rioux", 2019, "Correction: insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population"], ["Richard H Duerr", 2019, "Correction: insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population"], ["Jacques Cosnes", 2019, "Correction: insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population"], ["Tariq Ahmad", 2019, "Correction: insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population"], ["Luke Jostins", 2019, "Correction: insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population"], ["Jukka Koskela", 2019, "Correction: insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population"], ["Kimmo Kontula", 2019, "Correction: insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population"], ["Mark J Daly", 2019, "Correction: insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population"], ["Andre Franke", 2019, "Correction: insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population"], ["Rinse K Weersma", 2019, "Correction: insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population"], ["Elena Schiff", 2019, "Correction: insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population"], ["Orlaith Kelly Williams Turpin", 2019, "Mucosa-Associated Microbiota in Ileoanal Pouches May Contribute to Clinical Symptoms, Particularly Stool Frequency, Independent of Endoscopic Disease Activity"], ["Andrea Tyler", 2019, "Mucosa-Associated Microbiota in Ileoanal Pouches May Contribute to Clinical Symptoms, Particularly Stool Frequency, Independent of Endoscopic Disease Activity"], ["Zane Cohen", 2019, "Mucosa-Associated Microbiota in Ileoanal Pouches May Contribute to Clinical Symptoms, Particularly Stool Frequency, Independent of Endoscopic Disease Activity"], ["Nicole Li", 2019, "The prevalence and clinical associations of subclinical Sacroiliitis in inflammatory bowel disease"], ["Jonathan Chan", 2019, "The prevalence and clinical associations of subclinical Sacroiliitis in inflammatory bowel disease"], ["Michelle Smith", 2019, "The prevalence and clinical associations of subclinical Sacroiliitis in inflammatory bowel disease"], ["Robert D Inman", 2019, "The prevalence and clinical associations of subclinical Sacroiliitis in inflammatory bowel disease"], ["Girish Bajaj", 2019, "Tu1827\u2013Maintenance Levels of Vedolizumab Do Not Correlate with Clinical Remission in IBD Patients"], ["Jenna M Tessolini", 2019, "Tu1827\u2013Maintenance Levels of Vedolizumab Do Not Correlate with Clinical Remission in IBD Patients"], ["Vivian Huang", 2019, "Tu1827\u2013Maintenance Levels of Vedolizumab Do Not Correlate with Clinical Remission in IBD Patients"], ["Jim W O'Connell", 2019, "Tu1827\u2013Maintenance Levels of Vedolizumab Do Not Correlate with Clinical Remission in IBD Patients"], ["Aoibhlinn O'Toole", 2019, "Tu1827\u2013Maintenance Levels of Vedolizumab Do Not Correlate with Clinical Remission in IBD Patients"], ["Margaret Walshe", 2019, "Tu1831\u2013Use of Drug-Tolerant Assays in Inflammatory Bowel Disease; What Does It Tell Us?"], ["Joanne M Stempak", 2019, "Tu1831\u2013Use of Drug-Tolerant Assays in Inflammatory Bowel Disease; What Does It Tell Us?"], ["B Kabakchiev", 2017, "P793 Microbial composition in IBD may influence clinical symptoms independent of endoscopic activity"], ["MI Smith", 2017, "P793 Microbial composition in IBD may influence clinical symptoms independent of endoscopic activity"], ["A Mohammadi", 2017, "P793 Microbial composition in IBD may influence clinical symptoms independent of endoscopic activity"], ["G Nguyen", 2017, "P793 Microbial composition in IBD may influence clinical symptoms independent of endoscopic activity"], ["AH Steinhart", 2017, "P793 Microbial composition in IBD may influence clinical symptoms independent of endoscopic activity"], ["P Zezos", 2017, "P296 Persistent symptoms, CRP elevation and treatment changes over time in Crohn's disease patients are associated with bowel damage progression as expressed by deterioration \u2026"], ["GC Nguyen", 2017, "P296 Persistent symptoms, CRP elevation and treatment changes over time in Crohn's disease patients are associated with bowel damage progression as expressed by deterioration \u2026"], ["N Narula", 2017, "P296 Persistent symptoms, CRP elevation and treatment changes over time in Crohn's disease patients are associated with bowel damage progression as expressed by deterioration \u2026"], ["AV Weizman", 2017, "P296 Persistent symptoms, CRP elevation and treatment changes over time in Crohn's disease patients are associated with bowel damage progression as expressed by deterioration \u2026"], ["TP Chawla", 2017, "P296 Persistent symptoms, CRP elevation and treatment changes over time in Crohn's disease patients are associated with bowel damage progression as expressed by deterioration \u2026"], ["R Milgrom", 2017, "P296 Persistent symptoms, CRP elevation and treatment changes over time in Crohn's disease patients are associated with bowel damage progression as expressed by deterioration \u2026"], ["R Duerr", 2017, "P269 Phenotypic predictors of endoscopic recurrence after ileal resection for Crohn's disease: an NIDDK IBD Genetics Consortium prospective study"], ["JL Rioux", 2017, "P269 Phenotypic predictors of endoscopic recurrence after ileal resection for Crohn's disease: an NIDDK IBD Genetics Consortium prospective study"], ["T Haritunians", 2017, "P269 Phenotypic predictors of endoscopic recurrence after ileal resection for Crohn's disease: an NIDDK IBD Genetics Consortium prospective study"], ["D McGovern", 2017, "P269 Phenotypic predictors of endoscopic recurrence after ileal resection for Crohn's disease: an NIDDK IBD Genetics Consortium prospective study"], ["LP Schumm", 2017, "P269 Phenotypic predictors of endoscopic recurrence after ileal resection for Crohn's disease: an NIDDK IBD Genetics Consortium prospective study"], ["Y Sharma", 2017, "P269 Phenotypic predictors of endoscopic recurrence after ileal resection for Crohn's disease: an NIDDK IBD Genetics Consortium prospective study"], ["SR Brant", 2017, "P269 Phenotypic predictors of endoscopic recurrence after ileal resection for Crohn's disease: an NIDDK IBD Genetics Consortium prospective study"], ["J Cho", 2017, "P269 Phenotypic predictors of endoscopic recurrence after ileal resection for Crohn's disease: an NIDDK IBD Genetics Consortium prospective study"], ["T Greener", 2017, "P426 Supra-therapeutic infliximab levels are not associated with a higher risk of infection in IBD patients"], ["Grace W Ma", 2017, "Ileal pouch\u2013anal anastomosis for ulcerative colitis: a Canadian institution\u2019s experience"], ["E Zittan", 2017, "Ileal pouch\u2013anal anastomosis for ulcerative colitis: a Canadian institution\u2019s experience"], ["Z Cohen", 2017, "Ileal pouch\u2013anal anastomosis for ulcerative colitis: a Canadian institution\u2019s experience"], ["N Wong-Chong", 2017, "Ileal pouch\u2013anal anastomosis for ulcerative colitis: a Canadian institution\u2019s experience"], ["RS McLeod", 2017, "Ileal pouch\u2013anal anastomosis for ulcerative colitis: a Canadian institution\u2019s experience"], ["Amir Rumman", 2017, "Public versus private drug insurance and outcomes of patients requiring biologic therapies for inflammatory bowel disease"], ["Justina J Sam", 2017, "Public versus private drug insurance and outcomes of patients requiring biologic therapies for inflammatory bowel disease"], ["Roberto Candia", 2017, "Public versus private drug insurance and outcomes of patients requiring biologic therapies for inflammatory bowel disease"], ["Geoffrey C Nguyen", 2017, "Public versus private drug insurance and outcomes of patients requiring biologic therapies for inflammatory bowel disease"], ["Helen Macrae", 2017, "Rates and predictors of endoscopic and clinical recurrence after primary ileocolic resection for Crohn\u2019s disease"], ["Gordon Greenberg", 2017, "Rates and predictors of endoscopic and clinical recurrence after primary ileocolic resection for Crohn\u2019s disease"], ["Hillary Steinhart", 2017, "Rates and predictors of endoscopic and clinical recurrence after primary ileocolic resection for Crohn\u2019s disease"], ["Kyle Joshua Fortinsky", 2017, "Rates and predictors of endoscopic and clinical recurrence after primary ileocolic resection for Crohn\u2019s disease"], ["Robin McLeod", 2017, "Rates and predictors of endoscopic and clinical recurrence after primary ileocolic resection for Crohn\u2019s disease"], ["Felipe Bellolio", 2017, "Rates and predictors of endoscopic and clinical recurrence after primary ileocolic resection for Crohn\u2019s disease"], ["Judy Qiang", 2017, "Rates and predictors of endoscopic and clinical recurrence after primary ileocolic resection for Crohn\u2019s disease"], ["Dedrick E Moulton", 2017, "Genome-wide association study identifies African-specific susceptibility loci in African Americans with inflammatory bowel disease"], ["Themistocles Dassopoulos", 2017, "Genome-wide association study identifies African-specific susceptibility loci in African Americans with inflammatory bowel disease"], ["Michael E Zwick", 2017, "Genome-wide association study identifies African-specific susceptibility loci in African Americans with inflammatory bowel disease"], ["Peter Mannon", 2017, "Genome-wide association study identifies African-specific susceptibility loci in African Americans with inflammatory bowel disease"], ["Shehzad A Saeed", 2017, "Genome-wide association study identifies African-specific susceptibility loci in African Americans with inflammatory bowel disease"], ["John H Kwon", 2017, "Genome-wide association study identifies African-specific susceptibility loci in African Americans with inflammatory bowel disease"], ["Stephan R Targan", 2017, "Genome-wide association study identifies African-specific susceptibility loci in African Americans with inflammatory bowel disease"], ["Ferdouse Begum", 2017, "Genome-wide association study identifies African-specific susceptibility loci in African Americans with inflammatory bowel disease"], ["Howard Kader", 2017, "Genome-wide association study identifies African-specific susceptibility loci in African Americans with inflammatory bowel disease"], ["Rodney D Newberry", 2017, "Genome-wide association study identifies African-specific susceptibility loci in African Americans with inflammatory bowel disease"], ["Lisa W Datta", 2017, "Genome-wide association study identifies African-specific susceptibility loci in African Americans with inflammatory bowel disease"], ["John F Valentine", 2017, "Genome-wide association study identifies African-specific susceptibility loci in African Americans with inflammatory bowel disease"], ["Ming-Hsi Wang", 2017, "Genome-wide association study identifies African-specific susceptibility loci in African Americans with inflammatory bowel disease"], ["Hakon Hakonarson", 2017, "Genome-wide association study identifies African-specific susceptibility loci in African Americans with inflammatory bowel disease"], ["Jeffry Katz", 2017, "Genome-wide association study identifies African-specific susceptibility loci in African Americans with inflammatory bowel disease"], ["Richard Kellermayer", 2017, "Genome-wide association study identifies African-specific susceptibility loci in African Americans with inflammatory bowel disease"], ["Robert N Baldassano", 2017, "Genome-wide association study identifies African-specific susceptibility loci in African Americans with inflammatory bowel disease"], ["Chengrui Huang", 2017, "Genome-wide association study identifies African-specific susceptibility loci in African Americans with inflammatory bowel disease"], ["Kim L Isaacs", 2017, "Genome-wide association study identifies African-specific susceptibility loci in African Americans with inflammatory bowel disease"], ["Archana Kumar", 2017, "Genome-wide association study identifies African-specific susceptibility loci in African Americans with inflammatory bowel disease"], ["Bankole O Osuntokun", 2017, "Genome-wide association study identifies African-specific susceptibility loci in African Americans with inflammatory bowel disease"], ["Jeffrey S Hyams", 2017, "Genome-wide association study identifies African-specific susceptibility loci in African Americans with inflammatory bowel disease"], ["Mark Lazarev", 2017, "Genome-wide association study identifies African-specific susceptibility loci in African Americans with inflammatory bowel disease"], ["David T Okou", 2017, "Genome-wide association study identifies African-specific susceptibility loci in African Americans with inflammatory bowel disease"], ["John F Kuemmerle", 2017, "Genome-wide association study identifies African-specific susceptibility loci in African Americans with inflammatory bowel disease"], ["Lee A Denson", 2017, "Genome-wide association study identifies African-specific susceptibility loci in African Americans with inflammatory bowel disease"], ["Barbara S Kirschner", 2017, "Genome-wide association study identifies African-specific susceptibility loci in African Americans with inflammatory bowel disease"], ["Claire L Simpson", 2017, "Genome-wide association study identifies African-specific susceptibility loci in African Americans with inflammatory bowel disease"], ["Ellen Li", 2017, "Genome-wide association study identifies African-specific susceptibility loci in African Americans with inflammatory bowel disease"], ["Raymond K Cross", 2017, "Genome-wide association study identifies African-specific susceptibility loci in African Americans with inflammatory bowel disease"], ["Jenifer Seminerio", 2017, "Genome-wide association study identifies African-specific susceptibility loci in African Americans with inflammatory bowel disease"], ["John S Hanson", 2017, "Genome-wide association study identifies African-specific susceptibility loci in African Americans with inflammatory bowel disease"], ["Lisa J Herrinton", 2017, "Genome-wide association study identifies African-specific susceptibility loci in African Americans with inflammatory bowel disease"], ["Jarod Prince", 2017, "Genome-wide association study identifies African-specific susceptibility loci in African Americans with inflammatory bowel disease"], ["Kelly Thomas", 2017, "Genome-wide association study identifies African-specific susceptibility loci in African Americans with inflammatory bowel disease"], ["Michael D Kappelman", 2017, "Genome-wide association study identifies African-specific susceptibility loci in African Americans with inflammatory bowel disease"], ["Jason K Hou", 2017, "Genome-wide association study identifies African-specific susceptibility loci in African Americans with inflammatory bowel disease"], ["Jonathan P Bradfield", 2017, "Genome-wide association study identifies African-specific susceptibility loci in African Americans with inflammatory bowel disease"], ["Subra Kugathasan", 2017, "Genome-wide association study identifies African-specific susceptibility loci in African Americans with inflammatory bowel disease"], ["Sunny Z Hussain", 2017, "Genome-wide association study identifies African-specific susceptibility loci in African Americans with inflammatory bowel disease"], ["Zhenqiu Liu", 2017, "Genome-wide association study identifies African-specific susceptibility loci in African Americans with inflammatory bowel disease"], ["Gerald W Dryden", 2017, "Genome-wide association study identifies African-specific susceptibility loci in African Americans with inflammatory bowel disease"], ["Pankaj Chopra", 2017, "Genome-wide association study identifies African-specific susceptibility loci in African Americans with inflammatory bowel disease"], ["Suresh Venkateswaran", 2017, "Genome-wide association study identifies African-specific susceptibility loci in African Americans with inflammatory bowel disease"], ["Zhi Wei", 2017, "Genome-wide association study identifies African-specific susceptibility loci in African Americans with inflammatory bowel disease"], ["David J Cutler", 2017, "Genome-wide association study identifies African-specific susceptibility loci in African Americans with inflammatory bowel disease"], ["Antonio J Quiros", 2017, "Genome-wide association study identifies African-specific susceptibility loci in African Americans with inflammatory bowel disease"], ["Ashish S Patel", 2017, "Genome-wide association study identifies African-specific susceptibility loci in African Americans with inflammatory bowel disease"], ["Martin Zonca", 2017, "Genome-wide association study identifies African-specific susceptibility loci in African Americans with inflammatory bowel disease"], ["Tanvi A Dhere", 2017, "Genome-wide association study identifies African-specific susceptibility loci in African Americans with inflammatory bowel disease"], ["Jan-Micheal A Klapproth", 2017, "Genome-wide association study identifies African-specific susceptibility loci in African Americans with inflammatory bowel disease"], ["Jonathan S Alexander", 2017, "Genome-wide association study identifies African-specific susceptibility loci in African Americans with inflammatory bowel disease"], ["Sharon Dudley-Brown", 2017, "Genome-wide association study identifies African-specific susceptibility loci in African Americans with inflammatory bowel disease"], ["Ernest Seidman", 2016, "Association of host genome with intestinal microbial composition in a large healthy cohort"], ["Gabriel Moreno-Hagelsieb", 2016, "Association of host genome with intestinal microbial composition in a large healthy cohort"], ["Peter Higgins", 2016, "Association of host genome with intestinal microbial composition in a large healthy cohort"], ["Maria Cino", 2016, "Association of host genome with intestinal microbial composition in a large healthy cohort"], ["Leo Dieleman", 2016, "Association of host genome with intestinal microbial composition in a large healthy cohort"], ["Colette Deslandres", 2016, "Association of host genome with intestinal microbial composition in a large healthy cohort"], ["Jeff Hyams", 2016, "Association of host genome with intestinal microbial composition in a large healthy cohort"], ["GEM Project Research Consortium", 2016, "Association of host genome with intestinal microbial composition in a large healthy cohort"], ["David S Guttman", 2016, "Association of host genome with intestinal microbial composition in a large healthy cohort"], ["Bruce Vallance", 2016, "Association of host genome with intestinal microbial composition in a large healthy cohort"], ["Jerry McGrath", 2016, "Association of host genome with intestinal microbial composition in a large healthy cohort"], ["Charles Bernstein", 2016, "Association of host genome with intestinal microbial composition in a large healthy cohort"], ["Lee Denson", 2016, "Association of host genome with intestinal microbial composition in a large healthy cohort"], ["Denis O Krause", 2016, "Association of host genome with intestinal microbial composition in a large healthy cohort"], ["Andy Stadnyk", 2016, "Association of host genome with intestinal microbial composition in a large healthy cohort"], ["Anne Griffiths", 2016, "Association of host genome with intestinal microbial composition in a large healthy cohort"], ["John Marshall", 2016, "Association of host genome with intestinal microbial composition in a large healthy cohort"], ["Konstantin Shestopaloff", 2016, "Association of host genome with intestinal microbial composition in a large healthy cohort"], ["Wael El-Matary", 2016, "Association of host genome with intestinal microbial composition in a large healthy cohort"], ["Brian Feagan", 2016, "Association of host genome with intestinal microbial composition in a large healthy cohort"], ["Michael Surette", 2016, "Association of host genome with intestinal microbial composition in a large healthy cohort"], ["Maria Abreu", 2016, "Association of host genome with intestinal microbial composition in a large healthy cohort"], ["Tom Walters", 2016, "Association of host genome with intestinal microbial composition in a large healthy cohort"], ["Gilaad Kaplan", 2016, "Association of host genome with intestinal microbial composition in a large healthy cohort"], ["Scott Snapper", 2016, "Association of host genome with intestinal microbial composition in a large healthy cohort"], ["Lizhen Xu", 2016, "Association of host genome with intestinal microbial composition in a large healthy cohort"], ["Anthony Otley", 2016, "Association of host genome with intestinal microbial composition in a large healthy cohort"], ["Hien Huynh", 2016, "Association of host genome with intestinal microbial composition in a large healthy cohort"], ["Remo Panaccione", 2016, "Association of host genome with intestinal microbial composition in a large healthy cohort"], ["Paul Beck", 2016, "Association of host genome with intestinal microbial composition in a large healthy cohort"], ["Alain Bitton", 2016, "Association of host genome with intestinal microbial composition in a large healthy cohort"], ["Jeff Critch", 2016, "Association of host genome with intestinal microbial composition in a large healthy cohort"], ["Guy Aumais", 2016, "Association of host genome with intestinal microbial composition in a large healthy cohort"], ["Hans Herfarth", 2016, "Association of host genome with intestinal microbial composition in a large healthy cohort"], ["Brenda O'Connor", 2016, "Preoperative Anti\u2013tumor Necrosis Factor Therapy in Patients with Ulcerative Colitis Is Not Associated with an Increased Risk of Infectious and Noninfectious Complications After \u2026"], ["Helen M MacRae", 2016, "Preoperative Anti\u2013tumor Necrosis Factor Therapy in Patients with Ulcerative Colitis Is Not Associated with an Increased Risk of Infectious and Noninfectious Complications After \u2026"], ["Nathalie Wong-Chong", 2016, "Preoperative Anti\u2013tumor Necrosis Factor Therapy in Patients with Ulcerative Colitis Is Not Associated with an Increased Risk of Infectious and Noninfectious Complications After \u2026"], ["Gordon R Greenberg", 2016, "Preoperative Anti\u2013tumor Necrosis Factor Therapy in Patients with Ulcerative Colitis Is Not Associated with an Increased Risk of Infectious and Noninfectious Complications After \u2026"], ["Robin S McLeod", 2016, "Preoperative Anti\u2013tumor Necrosis Factor Therapy in Patients with Ulcerative Colitis Is Not Associated with an Increased Risk of Infectious and Noninfectious Complications After \u2026"], ["Claudia R Rivers", 2016, "Genetic predictors of benign course of ulcerative Colitis\u2014A North American inflammatory bowel disease genetics Consortium study"], ["David Binion", 2016, "Genetic predictors of benign course of ulcerative Colitis\u2014A North American inflammatory bowel disease genetics Consortium study"], ["Phillip P Schumm", 2016, "Genetic predictors of benign course of ulcerative Colitis\u2014A North American inflammatory bowel disease genetics Consortium study"], ["Matti Waterman", 2016, "Genetic predictors of benign course of ulcerative Colitis\u2014A North American inflammatory bowel disease genetics Consortium study"], ["Uri Kopylov", 2016, "Genetic predictors of benign course of ulcerative Colitis\u2014A North American inflammatory bowel disease genetics Consortium study"], ["Mohini Patel", 2016, "Genetic predictors of benign course of ulcerative Colitis\u2014A North American inflammatory bowel disease genetics Consortium study"], ["Jean F Colombel", 2016, "Genetic predictors of benign course of ulcerative Colitis\u2014A North American inflammatory bowel disease genetics Consortium study"], ["Gabrielle Boucher", 2016, "Genetic predictors of benign course of ulcerative Colitis\u2014A North American inflammatory bowel disease genetics Consortium study"], ["Stephan Brand", 2016, "A pleiotropic missense variant in SLC39A8 is associated with Crohn\u2019s disease and human gut microbiome composition"], ["Leif T\u00f6rkvist", 2016, "A pleiotropic missense variant in SLC39A8 is associated with Crohn\u2019s disease and human gut microbiome composition"], ["Mark Daly", 2016, "A pleiotropic missense variant in SLC39A8 is associated with Crohn\u2019s disease and human gut microbiome composition"], ["Lambertus Klei", 2016, "A pleiotropic missense variant in SLC39A8 is associated with Crohn\u2019s disease and human gut microbiome composition"], ["Mauro D'Amato", 2016, "A pleiotropic missense variant in SLC39A8 is associated with Crohn\u2019s disease and human gut microbiome composition"], ["Lisa A Simms", 2016, "A pleiotropic missense variant in SLC39A8 is associated with Crohn\u2019s disease and human gut microbiome composition"], ["Graham Radford-Smith", 2016, "A pleiotropic missense variant in SLC39A8 is associated with Crohn\u2019s disease and human gut microbiome composition"], ["Deborah D Proctor", 2016, "A pleiotropic missense variant in SLC39A8 is associated with Crohn\u2019s disease and human gut microbiome composition"], ["Jan-Hendrik Niess", 2016, "A pleiotropic missense variant in SLC39A8 is associated with Crohn\u2019s disease and human gut microbiome composition"], ["Dalin Li", 2016, "A pleiotropic missense variant in SLC39A8 is associated with Crohn\u2019s disease and human gut microbiome composition"], ["L Philip Schumm", 2016, "A pleiotropic missense variant in SLC39A8 is associated with Crohn\u2019s disease and human gut microbiome composition"], ["Jonathan Braun", 2016, "A pleiotropic missense variant in SLC39A8 is associated with Crohn\u2019s disease and human gut microbiome composition"], ["James Borneman", 2016, "A pleiotropic missense variant in SLC39A8 is associated with Crohn\u2019s disease and human gut microbiome composition"], ["J\u00fcrgen Glas", 2016, "A pleiotropic missense variant in SLC39A8 is associated with Crohn\u2019s disease and human gut microbiome composition"], ["Bernie Devlin", 2016, "A pleiotropic missense variant in SLC39A8 is associated with Crohn\u2019s disease and human gut microbiome composition"], ["Jean-Paul Achkar", 2016, "A pleiotropic missense variant in SLC39A8 is associated with Crohn\u2019s disease and human gut microbiome composition"], ["Yashoda Sharma", 2016, "A pleiotropic missense variant in SLC39A8 is associated with Crohn\u2019s disease and human gut microbiome composition"], ["Ken Y Hui", 2016, "A pleiotropic missense variant in SLC39A8 is associated with Crohn\u2019s disease and human gut microbiome composition"], ["Ashwin Ananthakrishnan", 2016, "A pleiotropic missense variant in SLC39A8 is associated with Crohn\u2019s disease and human gut microbiome composition"], ["Jonas Halfvarson", 2016, "A pleiotropic missense variant in SLC39A8 is associated with Crohn\u2019s disease and human gut microbiome composition"], ["Leonard Baidoo", 2016, "A pleiotropic missense variant in SLC39A8 is associated with Crohn\u2019s disease and human gut microbiome composition"], ["Miguel Regueiro", 2016, "A pleiotropic missense variant in SLC39A8 is associated with Crohn\u2019s disease and human gut microbiome composition"], ["Marla Dubinsky", 2016, "A pleiotropic missense variant in SLC39A8 is associated with Crohn\u2019s disease and human gut microbiome composition"], ["Jonathan P Jacobs", 2016, "A pleiotropic missense variant in SLC39A8 is associated with Crohn\u2019s disease and human gut microbiome composition"], ["Claudio Fiocchi", 2016, "A pleiotropic missense variant in SLC39A8 is associated with Crohn\u2019s disease and human gut microbiome composition"], ["Carsten B\u00fcning", 2016, "A pleiotropic missense variant in SLC39A8 is associated with Crohn\u2019s disease and human gut microbiome composition"], ["Romain Remark", 2016, "A frameshift in CSF2RB predominant among Ashkenazi Jews increases risk for Crohn's disease and reduces monocyte signaling via GM-CSF"], ["Peter Legnani", 2016, "A frameshift in CSF2RB predominant among Ashkenazi Jews increases risk for Crohn's disease and reduces monocyte signaling via GM-CSF"], ["Seth Lipka", 2016, "A frameshift in CSF2RB predominant among Ashkenazi Jews increases risk for Crohn's disease and reduces monocyte signaling via GM-CSF"], ["Adeeb Rahman", 2016, "A frameshift in CSF2RB predominant among Ashkenazi Jews increases risk for Crohn's disease and reduces monocyte signaling via GM-CSF"], ["Ling-Shiang Chuang", 2016, "A frameshift in CSF2RB predominant among Ashkenazi Jews increases risk for Crohn's disease and reduces monocyte signaling via GM-CSF"], ["Alexander Gusev", 2016, "A frameshift in CSF2RB predominant among Ashkenazi Jews increases risk for Crohn's disease and reduces monocyte signaling via GM-CSF"], ["Sacha Gnjatic", 2016, "A frameshift in CSF2RB predominant among Ashkenazi Jews increases risk for Crohn's disease and reduces monocyte signaling via GM-CSF"], ["Heriberto Fernandez-Hernandez", 2016, "A frameshift in CSF2RB predominant among Ashkenazi Jews increases risk for Crohn's disease and reduces monocyte signaling via GM-CSF"], ["L Phillip Schumm", 2016, "A frameshift in CSF2RB predominant among Ashkenazi Jews increases risk for Crohn's disease and reduces monocyte signaling via GM-CSF"], ["Sok Meng Evelyn Ng", 2016, "A frameshift in CSF2RB predominant among Ashkenazi Jews increases risk for Crohn's disease and reduces monocyte signaling via GM-CSF"], ["Clara Abraham", 2016, "A frameshift in CSF2RB predominant among Ashkenazi Jews increases risk for Crohn's disease and reduces monocyte signaling via GM-CSF"], ["Maria T Abreu", 2016, "A frameshift in CSF2RB predominant among Ashkenazi Jews increases risk for Crohn's disease and reduces monocyte signaling via GM-CSF"], ["Arthur Mortha", 2016, "A frameshift in CSF2RB predominant among Ashkenazi Jews increases risk for Crohn's disease and reduces monocyte signaling via GM-CSF"], ["Kent Taylor", 2016, "A frameshift in CSF2RB predominant among Ashkenazi Jews increases risk for Crohn's disease and reduces monocyte signaling via GM-CSF"], ["Marla J Dubinsky", 2016, "A frameshift in CSF2RB predominant among Ashkenazi Jews increases risk for Crohn's disease and reduces monocyte signaling via GM-CSF"], ["Wei Zhang", 2016, "A frameshift in CSF2RB predominant among Ashkenazi Jews increases risk for Crohn's disease and reduces monocyte signaling via GM-CSF"], ["Robert J Desnick", 2016, "A frameshift in CSF2RB predominant among Ashkenazi Jews increases risk for Crohn's disease and reduces monocyte signaling via GM-CSF"], ["Aleixo M Muise", 2016, "A frameshift in CSF2RB predominant among Ashkenazi Jews increases risk for Crohn's disease and reduces monocyte signaling via GM-CSF"], ["Bruce E Sands", 2016, "A frameshift in CSF2RB predominant among Ashkenazi Jews increases risk for Crohn's disease and reduces monocyte signaling via GM-CSF"], ["Miriam Merad", 2016, "A frameshift in CSF2RB predominant among Ashkenazi Jews increases risk for Crohn's disease and reduces monocyte signaling via GM-CSF"], ["Manuel Rivas", 2016, "A frameshift in CSF2RB predominant among Ashkenazi Jews increases risk for Crohn's disease and reduces monocyte signaling via GM-CSF"], ["Adam S Cheifetz", 2016, "A frameshift in CSF2RB predominant among Ashkenazi Jews increases risk for Crohn's disease and reduces monocyte signaling via GM-CSF"], ["Jody-Ann Facey", 2016, "A frameshift in CSF2RB predominant among Ashkenazi Jews increases risk for Crohn's disease and reduces monocyte signaling via GM-CSF"], ["Ariel Darvasi", 2016, "A frameshift in CSF2RB predominant among Ashkenazi Jews increases risk for Crohn's disease and reduces monocyte signaling via GM-CSF"], ["Todd Lencz", 2016, "A frameshift in CSF2RB predominant among Ashkenazi Jews increases risk for Crohn's disease and reduces monocyte signaling via GM-CSF"], ["James George", 2016, "A frameshift in CSF2RB predominant among Ashkenazi Jews increases risk for Crohn's disease and reduces monocyte signaling via GM-CSF"], ["Beatrice M Bowen", 2016, "A frameshift in CSF2RB predominant among Ashkenazi Jews increases risk for Crohn's disease and reduces monocyte signaling via GM-CSF"], ["Nai-Yun Hsu", 2016, "A frameshift in CSF2RB predominant among Ashkenazi Jews increases risk for Crohn's disease and reduces monocyte signaling via GM-CSF"], ["Nicole Villaverde", 2016, "A frameshift in CSF2RB predominant among Ashkenazi Jews increases risk for Crohn's disease and reduces monocyte signaling via GM-CSF"], ["Jerome I Rotter", 2016, "A frameshift in CSF2RB predominant among Ashkenazi Jews increases risk for Crohn's disease and reduces monocyte signaling via GM-CSF"], ["Itsik Pe\u2019er", 2016, "A frameshift in CSF2RB predominant among Ashkenazi Jews increases risk for Crohn's disease and reduces monocyte signaling via GM-CSF"], ["Jacob L McCauley", 2016, "A frameshift in CSF2RB predominant among Ashkenazi Jews increases risk for Crohn's disease and reduces monocyte signaling via GM-CSF"], ["Kaida Ning", 2016, "A frameshift in CSF2RB predominant among Ashkenazi Jews increases risk for Crohn's disease and reduces monocyte signaling via GM-CSF"], ["Elena R Schiff", 2016, "A frameshift in CSF2RB predominant among Ashkenazi Jews increases risk for Crohn's disease and reduces monocyte signaling via GM-CSF"], ["Hongyu Zhao", 2016, "A frameshift in CSF2RB predominant among Ashkenazi Jews increases risk for Crohn's disease and reduces monocyte signaling via GM-CSF"], ["Ellen J Scherl", 2016, "A frameshift in CSF2RB predominant among Ashkenazi Jews increases risk for Crohn's disease and reduces monocyte signaling via GM-CSF"], ["Tramy Luong", 2016, "A frameshift in CSF2RB predominant among Ashkenazi Jews increases risk for Crohn's disease and reduces monocyte signaling via GM-CSF"], ["Seymour Katz", 2016, "A frameshift in CSF2RB predominant among Ashkenazi Jews increases risk for Crohn's disease and reduces monocyte signaling via GM-CSF"], ["Martti F\u00e4rkkil\u00e4", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["A Bitton", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["Yang Luo", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["C Mathew", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["N Kennedy", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["Ashwin N Ananthakrishnan", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["Ingileif Jonsdottir", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["H Uhlig", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["J Glas", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["N Prescott", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["D Proctor", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["E Nimmo", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["C Abraham", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["MH Wang", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["C Lamb", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["JV Limbergen", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["J Randall", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["M Parkes", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["Unnur Thorsteinsdottir", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["Mauro D\u2019Amato", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["Graham A Heap", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["K de Lange", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["C Lees", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["S Kugathasan", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["Philippe Goyette", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["D Wilson", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["G Boucher", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["JM Stempak", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["Mitja I Kurki", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["Vito Annese", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["Paulina Paavola-Sakki", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["A Hart", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["JP Achkar", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["Lotta LE Koskinen", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["Marijn C Visschedijk", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["J Barrett", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["Beryl Cummings", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["C Mowatt", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["M Pollard", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["P\u00e4ivi Saavalainen", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["J Lee", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["UK IBD Genetics Consortium", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["S\u00f6ren Mucha", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["Daniel Gudbjartsson", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["D Rice", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["Frauke Degenhardt", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["Leena Halme", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["C Edwards", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["L Jostins", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["M Regueiro", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["PL Schumm", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["Kari Stefansson", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["A Simmons", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["A Nicole Desch", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["Maarit Lappalainen", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["P Fleshner", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["M Tremelling", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["Patrick Sulem", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["J Mansfield", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["Taru Tukiainen", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["J Satsangi", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["W Newman", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["SR Targan", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["C Hawkey", 2016, "A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis"], ["G Ma", 2016, "06 Modified 2-stage ileal pouch-anal anastomosis results in lower rate of anastomotic leak compared with traditional 2-stage surgery for ulcerative colitis."], ["R McLeod", 2016, "06 Modified 2-stage ileal pouch-anal anastomosis results in lower rate of anastomotic leak compared with traditional 2-stage surgery for ulcerative colitis."], ["Andrea D Tyler", 2016, "Intraepithelial lymphocytosis is a frequent finding in biopsies from ileal pouch\u2013anal anastomoses"], ["Joanna C Walsh", 2016, "Intraepithelial lymphocytosis is a frequent finding in biopsies from ileal pouch\u2013anal anastomoses"], ["Robert H Riddell", 2016, "Intraepithelial lymphocytosis is a frequent finding in biopsies from ileal pouch\u2013anal anastomoses"], ["Ofer Ben-Bassat", 2016, "Intraepithelial lymphocytosis is a frequent finding in biopsies from ileal pouch\u2013anal anastomoses"], ["David F Schaeffer", 2016, "Intraepithelial lymphocytosis is a frequent finding in biopsies from ileal pouch\u2013anal anastomoses"], ["Robert Inman", 2016, "Prevalence of Sacroiliitis in Inflammatory Bowel Disease Using a Standardized CT Screening Tool"], ["David Salonen", 2016, "Prevalence of Sacroiliitis in Inflammatory Bowel Disease Using a Standardized CT Screening Tool"], ["Ismail Sari", 2016, "Prevalence of Sacroiliitis in Inflammatory Bowel Disease Using a Standardized CT Screening Tool"], ["Nigil Haroon", 2016, "Prevalence of Sacroiliitis in Inflammatory Bowel Disease Using a Standardized CT Screening Tool"], ["Ken Croitoru", 2016, "Use of complementary and alternative medicine for inflammatory bowel disease is associated with worse adherence to conventional therapy: the COMPLIANT study"], ["Carol Landers", 2016, "TNFRSF1B Is Associated with ANCA in IBD"], ["Kent D Taylor", 2016, "TNFRSF1B Is Associated with ANCA in IBD"], ["Xiuqing Guo", 2016, "TNFRSF1B Is Associated with ANCA in IBD"], ["Yii-Der Ida Chen", 2016, "TNFRSF1B Is Associated with ANCA in IBD"], ["Marla C Dubinsky", 2016, "TNFRSF1B Is Associated with ANCA in IBD"], ["Katherine Hanigan", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Isabelle Cleynen", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Rebecca L Roberts", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Renata D\u2019Inc\u00e0", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Gareth Evans", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Timothy H Florin", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Denis Franchimont", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Gilles Jobin", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Regan Scott", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Steve Eyre", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Marc Schwartz", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Diana Eccles", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Dunecan Massey", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Peter A Bampton", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Jean-Francois Rahier", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Hazel E Drummond", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Laurent Peyrin-Biroulet", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Donald F Conrad", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Jaswinder Bull", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Richard Gearry", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Kullak Ublick", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Constantina Tsagarelis", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Kate Downes", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Karen Beck", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Bernadette Ebbs", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Paul Rutgeerts", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Chris Barnes", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Ian N Bruce", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Albert Cohen", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["John Ferguson", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Cathryn Edwards", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Sanjeev Bhaskar", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Oliver S Burren", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Krupa Krishnaprasad", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Laura Stronati", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Debby Laukens", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Anna Elliot", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Jan Aerts", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Hazel Arbury", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Sian Caesar", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Pierre Par\u00e9", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Jean-Frederick Colombel", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Darshna Dudakia", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Oliver J Brand", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Mohammed Azam Khan", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["David G Binion", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Raymond G Lahaie", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Jane M Andrews", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Ian C Lawrance", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Nicholas A Kennedy", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Andre Van Gossum", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Anthony Croft", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Linda Nelson", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Mario Cottone", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Arie Levine", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Jason M Swoger", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Chris M Clee", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["John MC Connell", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Andrew Dunham", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Paul Emery", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Debra Dutridge", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Corneliu A Bodea", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Paul Henderson", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Sok Meng Ng", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Anthony Attwood", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Morten H Vatn", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Andr\u00e9 Van Gossum", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Mathias Chamaillard", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Gillian Mahy", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Clarence Zhang", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Grant W Montgomery", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Johan Van Limbergen", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Jean-Pierre Hugot", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Hu Zhang", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Leila Amininijad", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Monica Milla", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Olivier Dewit", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Kirstin M Taylor", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Amanda J Bennett", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Murray Barclay", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Emilie Theatre", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Anthony J Balmforth", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Miguel D Regueiro", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Jake Byrnes", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Nicol Ferrier", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Sarah Edkins", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Harald Peeters", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Denise Spears", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Peter S Braund", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Anne Barton", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Steve R Brant", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["John Bowes", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Jason D Cooper", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Anna F Dominiczak", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Katarzyna Blaszczyk", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Gerome Breen", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Elizabeth Ruggiero", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Morris J Brown", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Frank Seibold", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Adam Auton", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Rebecca Roberts", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Joann Fultz", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["John Burton", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Francesca Bredin", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Dermot P McGovern", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["In\u00eas Barroso", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Michel Georges", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Arthur M Barrie III", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Stephen G Ball", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Amir Karban", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Edmond-Jean Bernard", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Niall Cardin", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["David M Evans", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Stephan Ripke", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Ioannis Oikonomou", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Marc L\u00e9mann", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Alison J Coffey", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Anne Farmer", 2016, "A method to exploit the structure of genetic ancestry space to enhance case-control studies"], ["Robyn Sharma", 2016, "Tu1920 Predictors and Characteristics of Psoriasiform Skin Lesions While on Infliximab Among Patients With Inflammatory Bowel Disease (IBD)"], ["Adam Weizman", 2016, "Tu1920 Predictors and Characteristics of Psoriasiform Skin Lesions While on Infliximab Among Patients With Inflammatory Bowel Disease (IBD)"], ["Sheri Maltais", 2016, "Tu1929 Association of Macro/Micro Nutrients With Endoscopic Disease Activity in Patients With Inflammatory Bowel Disease Suggests Possible Protective Role for Dietary Components"], ["Daniel DeCarvalho", 2016, "322 Chromatin Accessibility Differences Between CD4 T-Cells From Inflamed or Non-Inflamed Regions of the Gut in Inflammatory Bowel Diseases"], ["Tiago Medina", 2016, "322 Chromatin Accessibility Differences Between CD4 T-Cells From Inflamed or Non-Inflamed Regions of the Gut in Inflammatory Bowel Diseases"], ["Cheryl Arrowsmith", 2016, "322 Chromatin Accessibility Differences Between CD4 T-Cells From Inflamed or Non-Inflamed Regions of the Gut in Inflammatory Bowel Diseases"], ["Mathieu Lupien", 2016, "322 Chromatin Accessibility Differences Between CD4 T-Cells From Inflamed or Non-Inflamed Regions of the Gut in Inflammatory Bowel Diseases"], ["Alexander J Murison", 2016, "322 Chromatin Accessibility Differences Between CD4 T-Cells From Inflamed or Non-Inflamed Regions of the Gut in Inflammatory Bowel Diseases"], ["Aleksander Trajkovski", 2016, "Sa1959 Concentrations of 6-Thioguanine Nucleotide Correlate With Both Infliximab and Adalimumab Levels in Patients With Inflammatory Bowel Disease on Combination Therapy"], ["Andrew Paterson", 2016, "Su1900 Association of Functional Capacity of Fecal Microbiota With Intestinal Permeability in Healthy First Degree Relatives of Crohn's Disease Patients"], ["John Weinman", 2016, "Mo1840 Impact of Age on Beliefs About and Adherence to Medications in Patients With Inflammatory Bowel Disease: Results From the ALIGN Study"], ["Joel H Petersson", 2016, "Mo1840 Impact of Age on Beliefs About and Adherence to Medications in Patients With Inflammatory Bowel Disease: Results From the ALIGN Study"], ["Pascal Nurwakagari", 2016, "Mo1840 Impact of Age on Beliefs About and Adherence to Medications in Patients With Inflammatory Bowel Disease: Results From the ALIGN Study"], ["Pierre F Michetti", 2016, "Mo1840 Impact of Age on Beliefs About and Adherence to Medications in Patients With Inflammatory Bowel Disease: Results From the ALIGN Study"], ["Julia Sommer", 2016, "Mo1840 Impact of Age on Beliefs About and Adherence to Medications in Patients With Inflammatory Bowel Disease: Results From the ALIGN Study"], ["Brandee Pappalardo", 2016, "Mo1840 Impact of Age on Beliefs About and Adherence to Medications in Patients With Inflammatory Bowel Disease: Results From the ALIGN Study"], ["William Sandborn", 2016, "Tu1962 Looking Beyond Symptoms and Disease Activity to Define Disease Severity in Inflammatory Bowel Disease: Results of an IOIBD Specialist Panel"], ["Richard B Gearry", 2016, "Tu1962 Looking Beyond Symptoms and Disease Activity to Define Disease Severity in Inflammatory Bowel Disease: Results of an IOIBD Specialist Panel"], ["Peter L Lakatos", 2016, "Tu1962 Looking Beyond Symptoms and Disease Activity to Define Disease Severity in Inflammatory Bowel Disease: Results of an IOIBD Specialist Panel"], ["Jean-Frederic Colombel", 2016, "Tu1962 Looking Beyond Symptoms and Disease Activity to Define Disease Severity in Inflammatory Bowel Disease: Results of an IOIBD Specialist Panel"], ["R Balfour Sartor", 2016, "Tu1962 Looking Beyond Symptoms and Disease Activity to Define Disease Severity in Inflammatory Bowel Disease: Results of an IOIBD Specialist Panel"], ["Dermot McGovern", 2016, "Tu1962 Looking Beyond Symptoms and Disease Activity to Define Disease Severity in Inflammatory Bowel Disease: Results of an IOIBD Specialist Panel"], ["Stephen B Hanauer", 2016, "Tu1962 Looking Beyond Symptoms and Disease Activity to Define Disease Severity in Inflammatory Bowel Disease: Results of an IOIBD Specialist Panel"], ["Bjorn Moum", 2016, "Tu1962 Looking Beyond Symptoms and Disease Activity to Define Disease Severity in Inflammatory Bowel Disease: Results of an IOIBD Specialist Panel"], ["Cynthia B Whitman", 2016, "Tu1962 Looking Beyond Symptoms and Disease Activity to Define Disease Severity in Inflammatory Bowel Disease: Results of an IOIBD Specialist Panel"], ["Wolfgang Kruis", 2016, "Tu1962 Looking Beyond Symptoms and Disease Activity to Define Disease Severity in Inflammatory Bowel Disease: Results of an IOIBD Specialist Panel"], ["Ioannis Koutroubakis", 2016, "Tu1962 Looking Beyond Symptoms and Disease Activity to Define Disease Severity in Inflammatory Bowel Disease: Results of an IOIBD Specialist Panel"], ["Gerassimos J Mantzaris", 2016, "Tu1962 Looking Beyond Symptoms and Disease Activity to Define Disease Severity in Inflammatory Bowel Disease: Results of an IOIBD Specialist Panel"], ["Walter Reinisch", 2016, "Tu1962 Looking Beyond Symptoms and Disease Activity to Define Disease Severity in Inflammatory Bowel Disease: Results of an IOIBD Specialist Panel"], ["Curt Tysk", 2016, "Tu1962 Looking Beyond Symptoms and Disease Activity to Define Disease Severity in Inflammatory Bowel Disease: Results of an IOIBD Specialist Panel"], ["Christoph Gasche", 2016, "Tu1962 Looking Beyond Symptoms and Disease Activity to Define Disease Severity in Inflammatory Bowel Disease: Results of an IOIBD Specialist Panel"], ["Colm A O'Morain", 2016, "Tu1962 Looking Beyond Symptoms and Disease Activity to Define Disease Severity in Inflammatory Bowel Disease: Results of an IOIBD Specialist Panel"], ["Brennan Spiegel", 2016, "Tu1962 Looking Beyond Symptoms and Disease Activity to Define Disease Severity in Inflammatory Bowel Disease: Results of an IOIBD Specialist Panel"], ["Silvio Danese", 2016, "Tu1962 Looking Beyond Symptoms and Disease Activity to Define Disease Severity in Inflammatory Bowel Disease: Results of an IOIBD Specialist Panel"], ["Corey A Siegel", 2016, "Tu1962 Looking Beyond Symptoms and Disease Activity to Define Disease Severity in Inflammatory Bowel Disease: Results of an IOIBD Specialist Panel"], ["Francesco Pallone", 2016, "Tu1962 Looking Beyond Symptoms and Disease Activity to Define Disease Severity in Inflammatory Bowel Disease: Results of an IOIBD Specialist Panel"], ["Simon Travis", 2016, "Tu1962 Looking Beyond Symptoms and Disease Activity to Define Disease Severity in Inflammatory Bowel Disease: Results of an IOIBD Specialist Panel"], ["Gerhard Rogler", 2016, "Tu1962 Looking Beyond Symptoms and Disease Activity to Define Disease Severity in Inflammatory Bowel Disease: Results of an IOIBD Specialist Panel"], ["Julian Pan\u00e9s", 2016, "Tu1962 Looking Beyond Symptoms and Disease Activity to Define Disease Severity in Inflammatory Bowel Disease: Results of an IOIBD Specialist Panel"], ["Siew C Ng", 2016, "Tu1962 Looking Beyond Symptoms and Disease Activity to Define Disease Severity in Inflammatory Bowel Disease: Results of an IOIBD Specialist Panel"], ["Edward V Loftus", 2016, "Tu1962 Looking Beyond Symptoms and Disease Activity to Define Disease Severity in Inflammatory Bowel Disease: Results of an IOIBD Specialist Panel"], ["Geert R D'Haens", 2016, "Tu1962 Looking Beyond Symptoms and Disease Activity to Define Disease Severity in Inflammatory Bowel Disease: Results of an IOIBD Specialist Panel"], ["Sebastian Scheer", 2016, "Su1884 Influence of the Microbiome on Epigenetic Mechanisms in Inflammatory Bowel Disease (IBD)"], ["Colby Zaph", 2016, "Su1884 Influence of the Microbiome on Epigenetic Mechanisms in Inflammatory Bowel Disease (IBD)"], ["Morgan Rosenberg", 2016, "Infliximab to treat refractory inflammation after pelvic pouch surgery for ulcerative colitis"], ["P Michetti", 2016, "Effect of age on beliefs about and adherence to medications in patients with inflammatory bowel disease: results from the ALIGN study"], ["J Weinman", 2016, "Effect of age on beliefs about and adherence to medications in patients with inflammatory bowel disease: results from the ALIGN study"], ["P Nurwakagari", 2016, "Effect of age on beliefs about and adherence to medications in patients with inflammatory bowel disease: results from the ALIGN study"], ["J Petersson", 2016, "Effect of age on beliefs about and adherence to medications in patients with inflammatory bowel disease: results from the ALIGN study"], ["E Louis", 2016, "Effect of age on beliefs about and adherence to medications in patients with inflammatory bowel disease: results from the ALIGN study"], ["J Sommer", 2016, "Effect of age on beliefs about and adherence to medications in patients with inflammatory bowel disease: results from the ALIGN study"], ["L Peyrin-Biroulet", 2016, "Effect of age on beliefs about and adherence to medications in patients with inflammatory bowel disease: results from the ALIGN study"], ["B Pappalardo", 2016, "Effect of age on beliefs about and adherence to medications in patients with inflammatory bowel disease: results from the ALIGN study"], ["O Kelly", 2016, "Sacroiliitis is under-recognised in inflammatory bowel disease and is associated with previous arthritis and inflammatory Crohn's phenotype"], ["R Inman", 2016, "Sacroiliitis is under-recognised in inflammatory bowel disease and is associated with previous arthritis and inflammatory Crohn's phenotype"], ["J Chan", 2016, "Sacroiliitis is under-recognised in inflammatory bowel disease and is associated with previous arthritis and inflammatory Crohn's phenotype"], ["N Li", 2016, "Sacroiliitis is under-recognised in inflammatory bowel disease and is associated with previous arthritis and inflammatory Crohn's phenotype"], ["J Panes", 2016, "Looking beyond symptoms and disease activity to define disease severity in inflammatory bowel disease: results of an IOIBD specialist panel"], ["S Hanauer", 2016, "Looking beyond symptoms and disease activity to define disease severity in inflammatory bowel disease: results of an IOIBD specialist panel"], ["S Ng", 2016, "Looking beyond symptoms and disease activity to define disease severity in inflammatory bowel disease: results of an IOIBD specialist panel"], ["E Loftus", 2016, "Looking beyond symptoms and disease activity to define disease severity in inflammatory bowel disease: results of an IOIBD specialist panel"], ["B Sands", 2016, "Looking beyond symptoms and disease activity to define disease severity in inflammatory bowel disease: results of an IOIBD specialist panel"], ["C Whitman", 2016, "Looking beyond symptoms and disease activity to define disease severity in inflammatory bowel disease: results of an IOIBD specialist panel"], ["B Moum", 2016, "Looking beyond symptoms and disease activity to define disease severity in inflammatory bowel disease: results of an IOIBD specialist panel"], ["C Siegel", 2016, "Looking beyond symptoms and disease activity to define disease severity in inflammatory bowel disease: results of an IOIBD specialist panel"], ["P Lakatos", 2016, "Looking beyond symptoms and disease activity to define disease severity in inflammatory bowel disease: results of an IOIBD specialist panel"], ["S Travis", 2016, "Looking beyond symptoms and disease activity to define disease severity in inflammatory bowel disease: results of an IOIBD specialist panel"], ["R Gearry", 2016, "Looking beyond symptoms and disease activity to define disease severity in inflammatory bowel disease: results of an IOIBD specialist panel"], ["I Koutroubakis", 2016, "Looking beyond symptoms and disease activity to define disease severity in inflammatory bowel disease: results of an IOIBD specialist panel"], ["B Sartor", 2016, "Looking beyond symptoms and disease activity to define disease severity in inflammatory bowel disease: results of an IOIBD specialist panel"], ["G D'Haens", 2016, "Looking beyond symptoms and disease activity to define disease severity in inflammatory bowel disease: results of an IOIBD specialist panel"], ["JF Colombel", 2016, "Looking beyond symptoms and disease activity to define disease severity in inflammatory bowel disease: results of an IOIBD specialist panel"], ["C Tysk", 2016, "Looking beyond symptoms and disease activity to define disease severity in inflammatory bowel disease: results of an IOIBD specialist panel"], ["R Panaccione", 2016, "Looking beyond symptoms and disease activity to define disease severity in inflammatory bowel disease: results of an IOIBD specialist panel"], ["A Griffiths", 2016, "Looking beyond symptoms and disease activity to define disease severity in inflammatory bowel disease: results of an IOIBD specialist panel"], ["F Pallone", 2016, "Looking beyond symptoms and disease activity to define disease severity in inflammatory bowel disease: results of an IOIBD specialist panel"], ["S Danese", 2016, "Looking beyond symptoms and disease activity to define disease severity in inflammatory bowel disease: results of an IOIBD specialist panel"], ["G Mantzaris", 2016, "Looking beyond symptoms and disease activity to define disease severity in inflammatory bowel disease: results of an IOIBD specialist panel"], ["W Reinisch", 2016, "Looking beyond symptoms and disease activity to define disease severity in inflammatory bowel disease: results of an IOIBD specialist panel"], ["W Kruis", 2016, "Looking beyond symptoms and disease activity to define disease severity in inflammatory bowel disease: results of an IOIBD specialist panel"], ["C Bernstein", 2016, "Looking beyond symptoms and disease activity to define disease severity in inflammatory bowel disease: results of an IOIBD specialist panel"], ["W Sandborn", 2016, "Looking beyond symptoms and disease activity to define disease severity in inflammatory bowel disease: results of an IOIBD specialist panel"], ["R Riddell", 2016, "Looking beyond symptoms and disease activity to define disease severity in inflammatory bowel disease: results of an IOIBD specialist panel"], ["B Feagan", 2016, "Looking beyond symptoms and disease activity to define disease severity in inflammatory bowel disease: results of an IOIBD specialist panel"], ["C O'Morain", 2016, "Looking beyond symptoms and disease activity to define disease severity in inflammatory bowel disease: results of an IOIBD specialist panel"], ["B Spiegel", 2016, "Looking beyond symptoms and disease activity to define disease severity in inflammatory bowel disease: results of an IOIBD specialist panel"], ["A Amiot", 2016, "Post-induction adalimumab drug levels predict clinical and laboratory remission at week 24 in patients with Crohn\u2019s disease"], ["A Buisson", 2016, "Post-induction adalimumab drug levels predict clinical and laboratory remission at week 24 in patients with Crohn\u2019s disease"], ["F Carbonnel", 2016, "Post-induction adalimumab drug levels predict clinical and laboratory remission at week 24 in patients with Crohn\u2019s disease"], ["S Nancey11", 2016, "Post-induction adalimumab drug levels predict clinical and laboratory remission at week 24 in patients with Crohn\u2019s disease"], ["X Roblin12", 2016, "Post-induction adalimumab drug levels predict clinical and laboratory remission at week 24 in patients with Crohn\u2019s disease"], ["X Treton", 2016, "Post-induction adalimumab drug levels predict clinical and laboratory remission at week 24 in patients with Crohn\u2019s disease"], ["B Pariente", 2016, "Post-induction adalimumab drug levels predict clinical and laboratory remission at week 24 in patients with Crohn\u2019s disease"], ["JC Grimaud", 2016, "Post-induction adalimumab drug levels predict clinical and laboratory remission at week 24 in patients with Crohn\u2019s disease"], ["R Altwegg14", 2016, "Post-induction adalimumab drug levels predict clinical and laboratory remission at week 24 in patients with Crohn\u2019s disease"], ["A Bourrier10", 2016, "Post-induction adalimumab drug levels predict clinical and laboratory remission at week 24 in patients with Crohn\u2019s disease"], ["A Noureille", 2016, "Post-induction adalimumab drug levels predict clinical and laboratory remission at week 24 in patients with Crohn\u2019s disease"], ["P Marteau13", 2016, "Post-induction adalimumab drug levels predict clinical and laboratory remission at week 24 in patients with Crohn\u2019s disease"], ["J Filippi", 2016, "Post-induction adalimumab drug levels predict clinical and laboratory remission at week 24 in patients with Crohn\u2019s disease"], ["John Rioux", 2016, "P-175 Pleiotropic Effects of Novel Functional LRRK2 Variation on Crohn's Disease and Parkinson's Disease Risk"], ["Itsik Pe'er", 2016, "P-175 Pleiotropic Effects of Novel Functional LRRK2 Variation on Crohn's Disease and Parkinson's Disease Risk"], ["Eric Schadt", 2016, "P-175 Pleiotropic Effects of Novel Functional LRRK2 Variation on Crohn's Disease and Parkinson's Disease Risk"], ["Tatiana Foroud", 2016, "P-175 Pleiotropic Effects of Novel Functional LRRK2 Variation on Crohn's Disease and Parkinson's Disease Risk"], ["Shai Carmi", 2016, "P-175 Pleiotropic Effects of Novel Functional LRRK2 Variation on Crohn's Disease and Parkinson's Disease Risk"], ["Ken Hui", 2016, "P-175 Pleiotropic Effects of Novel Functional LRRK2 Variation on Crohn's Disease and Parkinson's Disease Risk"], ["Steven Brant", 2016, "P-175 Pleiotropic Effects of Novel Functional LRRK2 Variation on Crohn's Disease and Parkinson's Disease Risk"], ["Jianzhong Hu", 2016, "P-175 Pleiotropic Effects of Novel Functional LRRK2 Variation on Crohn's Disease and Parkinson's Disease Risk"], ["Nathan Pankratz", 2016, "P-175 Pleiotropic Effects of Novel Functional LRRK2 Variation on Crohn's Disease and Parkinson's Disease Risk"], ["Judy Cho", 2016, "P-175 Pleiotropic Effects of Novel Functional LRRK2 Variation on Crohn's Disease and Parkinson's Disease Risk"], ["Harry Ostrer", 2016, "P-175 Pleiotropic Effects of Novel Functional LRRK2 Variation on Crohn's Disease and Parkinson's Disease Risk"], ["Richard Duerr", 2016, "P-175 Pleiotropic Effects of Novel Functional LRRK2 Variation on Crohn's Disease and Parkinson's Disease Risk"], ["Jane Burns", 2016, "Low fecal calprotectin correlates with histological remission and mucosal healing in ulcerative colitis and colonic Crohn's disease"], ["Gert Van Assche", 2016, "Low fecal calprotectin correlates with histological remission and mucosal healing in ulcerative colitis and colonic Crohn's disease"], ["D Kevans", 2016, "Characterization of intestinal microbiota in ulcerative colitis patients with and without primary sclerosing cholangitis"], ["D Gevers", 2016, "Characterization of intestinal microbiota in ulcerative colitis patients with and without primary sclerosing cholangitis"], ["JR Hov", 2016, "Characterization of intestinal microbiota in ulcerative colitis patients with and without primary sclerosing cholangitis"], ["TH Karlsen", 2016, "Characterization of intestinal microbiota in ulcerative colitis patients with and without primary sclerosing cholangitis"], ["AD Tyler", 2016, "Characterization of intestinal microbiota in ulcerative colitis patients with and without primary sclerosing cholangitis"], ["GG Kaplan", 2016, "Characterization of intestinal microbiota in ulcerative colitis patients with and without primary sclerosing cholangitis"], ["MH Vatn", 2016, "Characterization of intestinal microbiota in ulcerative colitis patients with and without primary sclerosing cholangitis"], ["B Eksteen", 2016, "Characterization of intestinal microbiota in ulcerative colitis patients with and without primary sclerosing cholangitis"], ["KK J\u00f8rgensen", 2016, "Characterization of intestinal microbiota in ulcerative colitis patients with and without primary sclerosing cholangitis"], ["K Holm", 2016, "Characterization of intestinal microbiota in ulcerative colitis patients with and without primary sclerosing cholangitis"], ["Claire Bewshea", 2016, "Clinical features and HLA association of 5-aminosalicylate (5-ASA)-induced nephrotoxicity in inflammatory bowel disease"], ["Dorien Buurman", 2016, "Clinical features and HLA association of 5-aminosalicylate (5-ASA)-induced nephrotoxicity in inflammatory bowel disease"], ["Abhey Singh", 2016, "Clinical features and HLA association of 5-aminosalicylate (5-ASA)-induced nephrotoxicity in inflammatory bowel disease"], ["John Beckly", 2016, "Clinical features and HLA association of 5-aminosalicylate (5-ASA)-induced nephrotoxicity in inflammatory bowel disease"], ["Kenji So", 2016, "Clinical features and HLA association of 5-aminosalicylate (5-ASA)-induced nephrotoxicity in inflammatory bowel disease"], ["Naomi Edney", 2016, "Clinical features and HLA association of 5-aminosalicylate (5-ASA)-induced nephrotoxicity in inflammatory bowel disease"], ["Mike Weedon", 2016, "Clinical features and HLA association of 5-aminosalicylate (5-ASA)-induced nephrotoxicity in inflammatory bowel disease"], ["Rakesh Chaudhary", 2016, "Clinical features and HLA association of 5-aminosalicylate (5-ASA)-induced nephrotoxicity in inflammatory bowel disease"], ["Jo Knight", 2016, "IBD genetic risk profile in healthy first-degree relatives of Crohn\u2019s disease patients"], ["GEM Project", 2016, "IBD genetic risk profile in healthy first-degree relatives of Crohn\u2019s disease patients"], ["Venus Onay", 2016, "IBD genetic risk profile in healthy first-degree relatives of Crohn\u2019s disease patients"], ["David C Wilson", 2016, "Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study"], ["Johannes R Hov", 2016, "Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study"], ["Sebastian Zeissig", 2016, "Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study"], ["John Mansfield", 2016, "Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study"], ["Charlie W Lees", 2016, "Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study"], ["Vibeke Andersen", 2016, "Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study"], ["Lynnette R Ferguson", 2016, "Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study"], ["Limas Kupcinskas", 2016, "Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study"], ["James C Lee", 2016, "Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study"], ["Hailang Huang", 2016, "Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study"], ["Miles Parkes", 2016, "Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study"], ["Andrea E Van Der Meulen-De", 2016, "Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study"], ["Emilie Th\u00e9\u00e2tre", 2016, "Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study"], ["Stephan Schreiber", 2016, "Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study"], ["Jack Satsangi", 2016, "Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study"], ["International Inflammatory Bowel Disease Genetics Consortium", 2016, "Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study"], ["C Rust", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["G Dalekos", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["C Rupp", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["CL Bowlus", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["R Alberts", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["T Folseraas", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["KM Boberg", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["A Cheung", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["A Floreani", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["A Bergquist", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["A Pares", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["P Milkiewicz", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["CA Anderson", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["M Farkkila", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["GM Hirschfield", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["B de Vries", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["F Imhann", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["L Tittmann", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["J Eaton", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["JZ Liu", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["J Lofberg", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["AL Mason", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["RN Sandford", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["D Ellinghaus", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["E Melum", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["C Schramm", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["M Sterneck", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["A Teufel", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["SM Rushbrook", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["TJ Weismuller", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["EA Festen", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["E Goode", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["D Alvaro", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["KN Lazaridis", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["MP Manns", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["T Muller", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["F Sampaziotis", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["EM de Vries", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["C Wijmenga", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["M Marzioni", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["V Leppa", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["BD Juran", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["E Bjornsson", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["RK Weersma", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["RW Chapman", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["E Schrumpf", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["L Vallier", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["CY Ponsioen", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["U Beuers", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["O Chazouilleres", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["B Srivastava", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["S Hohenester", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["AV Vila", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["G Alexander", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["HU Marschall", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["K Zachou", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["P Invernizzi", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["DN Gotthardt", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["B van Hoek", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["X Jiang", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["A Franke", 2016, "Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis"], ["A Paterson", 2016, "Program and Abstracts from the Canadian Digestive Diseases Week\u0192 2016"], ["D Guttman", 2016, "Program and Abstracts from the Canadian Digestive Diseases Week\u0192 2016"], ["H Horton", 2016, "A validated web\u2010based tool to display individualised Crohn's disease predicted outcomes based on clinical, serologic and genetic variables"], ["A Levy", 2016, "A validated web\u2010based tool to display individualised Crohn's disease predicted outcomes based on clinical, serologic and genetic variables"], ["S Dezfoli", 2016, "A validated web\u2010based tool to display individualised Crohn's disease predicted outcomes based on clinical, serologic and genetic variables"], ["M Baek", 2016, "A validated web\u2010based tool to display individualised Crohn's disease predicted outcomes based on clinical, serologic and genetic variables"], ["KD Thompson", 2016, "A validated web\u2010based tool to display individualised Crohn's disease predicted outcomes based on clinical, serologic and genetic variables"], ["SK Stewart", 2016, "A validated web\u2010based tool to display individualised Crohn's disease predicted outcomes based on clinical, serologic and genetic variables"], ["PW Rice", 2016, "A validated web\u2010based tool to display individualised Crohn's disease predicted outcomes based on clinical, serologic and genetic variables"], ["MC Dubinsky", 2016, "A validated web\u2010based tool to display individualised Crohn's disease predicted outcomes based on clinical, serologic and genetic variables"], ["DP McGovern", 2016, "A validated web\u2010based tool to display individualised Crohn's disease predicted outcomes based on clinical, serologic and genetic variables"], ["CA Siegel", 2016, "A validated web\u2010based tool to display individualised Crohn's disease predicted outcomes based on clinical, serologic and genetic variables"], ["LS Siegel", 2016, "A validated web\u2010based tool to display individualised Crohn's disease predicted outcomes based on clinical, serologic and genetic variables"], ["T Mackenzie", 2016, "A validated web\u2010based tool to display individualised Crohn's disease predicted outcomes based on clinical, serologic and genetic variables"], ["PS Dulai", 2016, "A validated web\u2010based tool to display individualised Crohn's disease predicted outcomes based on clinical, serologic and genetic variables"], ["Mark M Sasaki", 2016, "Whole-exome Sequence Analysis Implicates Rare Il17REL Variants in Familial and Sporadic Inflammatory Bowel Disease"], ["Stacy A Kahn", 2016, "Whole-exome Sequence Analysis Implicates Rare Il17REL Variants in Familial and Sporadic Inflammatory Bowel Disease"], ["Kenan Onel", 2016, "Whole-exome Sequence Analysis Implicates Rare Il17REL Variants in Familial and Sporadic Inflammatory Bowel Disease"], ["Riyue Bao", 2016, "Whole-exome Sequence Analysis Implicates Rare Il17REL Variants in Familial and Sporadic Inflammatory Bowel Disease"], ["Eric A Hungate", 2016, "Whole-exome Sequence Analysis Implicates Rare Il17REL Variants in Familial and Sporadic Inflammatory Bowel Disease"], ["Andrew D Skol", 2016, "Whole-exome Sequence Analysis Implicates Rare Il17REL Variants in Familial and Sporadic Inflammatory Bowel Disease"], ["James M Allan", 2016, "Whole-exome Sequence Analysis Implicates Rare Il17REL Variants in Familial and Sporadic Inflammatory Bowel Disease"], ["Lei Huang", 2016, "Whole-exome Sequence Analysis Implicates Rare Il17REL Variants in Familial and Sporadic Inflammatory Bowel Disease"], ["Sasha Taleban", 2016, "Ocular manifestations in inflammatory bowel disease are associated with other extra-intestinal manifestations, gender, and genes implicated in other immune-related traits"], ["Eric A Vasiliauskas", 2016, "Ocular manifestations in inflammatory bowel disease are associated with other extra-intestinal manifestations, gender, and genes implicated in other immune-related traits"], ["Andrew Ippoliti", 2016, "Ocular manifestations in inflammatory bowel disease are associated with other extra-intestinal manifestations, gender, and genes implicated in other immune-related traits"], ["Gil Y Melmed", 2016, "Ocular manifestations in inflammatory bowel disease are associated with other extra-intestinal manifestations, gender, and genes implicated in other immune-related traits"], ["David Q Shih", 2016, "Ocular manifestations in inflammatory bowel disease are associated with other extra-intestinal manifestations, gender, and genes implicated in other immune-related traits"], ["Nicola L Jones", 2015, "Microbial disruption of autophagy alters expression of the RISC component AGO2, a critical regulator of the miRNA silencing pathway"], ["Laura Greenfield", 2015, "Microbial disruption of autophagy alters expression of the RISC component AGO2, a critical regulator of the miRNA silencing pathway"], ["Deepa Raju", 2015, "Microbial disruption of autophagy alters expression of the RISC component AGO2, a critical regulator of the miRNA silencing pathway"], ["Heidi Mascarenhas", 2015, "Microbial disruption of autophagy alters expression of the RISC component AGO2, a critical regulator of the miRNA silencing pathway"], ["David M Rodrigues", 2015, "Microbial disruption of autophagy alters expression of the RISC component AGO2, a critical regulator of the miRNA silencing pathway"], ["Esther Galindo-Mata", 2015, "Microbial disruption of autophagy alters expression of the RISC component AGO2, a critical regulator of the miRNA silencing pathway"], ["Majd Abdullah", 2015, "Microbial disruption of autophagy alters expression of the RISC component AGO2, a critical regulator of the miRNA silencing pathway"], ["Michal Sibony", 2015, "Microbial disruption of autophagy alters expression of the RISC component AGO2, a critical regulator of the miRNA silencing pathway"], ["Ted Wu", 2015, "Microbial disruption of autophagy alters expression of the RISC component AGO2, a critical regulator of the miRNA silencing pathway"], ["Dana J Philpott", 2015, "Microbial disruption of autophagy alters expression of the RISC component AGO2, a critical regulator of the miRNA silencing pathway"], ["Curtis Huttenhower", 2015, "Associations between host gene expression, the mucosal microbiome, and clinical outcome in the pelvic pouch of patients with inflammatory bowel disease"], ["Levi Waldron", 2015, "Associations between host gene expression, the mucosal microbiome, and clinical outcome in the pelvic pouch of patients with inflammatory bowel disease"], ["Xochitl C Morgan", 2015, "Associations between host gene expression, the mucosal microbiome, and clinical outcome in the pelvic pouch of patients with inflammatory bowel disease"], ["Dirk Gevers", 2015, "Associations between host gene expression, the mucosal microbiome, and clinical outcome in the pelvic pouch of patients with inflammatory bowel disease"], ["Timothy L Tickle", 2015, "Associations between host gene expression, the mucosal microbiome, and clinical outcome in the pelvic pouch of patients with inflammatory bowel disease"], ["Linda WH Kao", 2015, "Characterization of genetic loci that affect susceptibility to inflammatory bowel diseases in African Americans"], ["Anna Di Rienzo", 2015, "Characterization of genetic loci that affect susceptibility to inflammatory bowel diseases in African Americans"], ["Jeffrey Katz", 2015, "Characterization of genetic loci that affect susceptibility to inflammatory bowel diseases in African Americans"], ["Ann Silverman", 2015, "Characterization of genetic loci that affect susceptibility to inflammatory bowel diseases in African Americans"], ["Robert P Kimberly", 2015, "Characterization of genetic loci that affect susceptibility to inflammatory bowel diseases in African Americans"], ["Joseph C Maranville", 2015, "Characterization of genetic loci that affect susceptibility to inflammatory bowel diseases in African Americans"], ["Shannon Ellis", 2015, "Characterization of genetic loci that affect susceptibility to inflammatory bowel diseases in African Americans"], ["S Louis Bridges", 2015, "Characterization of genetic loci that affect susceptibility to inflammatory bowel diseases in African Americans"], ["Kelly E Kachelries", 2015, "Characterization of genetic loci that affect susceptibility to inflammatory bowel diseases in African Americans"], ["Ashish Patel", 2015, "Characterization of genetic loci that affect susceptibility to inflammatory bowel diseases in African Americans"], ["Shehzad Saeed", 2015, "Characterization of genetic loci that affect susceptibility to inflammatory bowel diseases in African Americans"], ["Stephen S Rich", 2015, "Characterization of genetic loci that affect susceptibility to inflammatory bowel diseases in African Americans"], ["Gert A Van Assche", 2015, "Higher Adalimumab Drug Levels Are Associated With Clinical and Endoscopic Remission in Patients With Crohn\u2019s Disease"], ["Justine A Ellis", 2015, "Genetic sharing and heritability of paediatric age of onset autoimmune diseases"], ["Caterina Strisciuglio", 2015, "Genetic sharing and heritability of paediatric age of onset autoimmune diseases"], ["Elena Resnick", 2015, "Genetic sharing and heritability of paediatric age of onset autoimmune diseases"], ["Maede Mohebnasab", 2015, "Genetic sharing and heritability of paediatric age of onset autoimmune diseases"], ["Fengxiang Wang", 2015, "Genetic sharing and heritability of paediatric age of onset autoimmune diseases"], ["Stephen L Guthery", 2015, "Genetic sharing and heritability of paediatric age of onset autoimmune diseases"], ["Benedicte A Lie", 2015, "Genetic sharing and heritability of paediatric age of onset autoimmune diseases"], ["Jordan S Orange", 2015, "Genetic sharing and heritability of paediatric age of onset autoimmune diseases"], ["Helen Chapel", 2015, "Genetic sharing and heritability of paediatric age of onset autoimmune diseases"], ["Sihai D Zhao", 2015, "Genetic sharing and heritability of paediatric age of onset autoimmune diseases"], ["Yun R Li", 2015, "Genetic sharing and heritability of paediatric age of onset autoimmune diseases"], ["Elena Perez", 2015, "Genetic sharing and heritability of paediatric age of onset autoimmune diseases"], ["Dimitri S Monos", 2015, "Genetic sharing and heritability of paediatric age of onset autoimmune diseases"], ["Joseph T Glessner", 2015, "Genetic sharing and heritability of paediatric age of onset autoimmune diseases"], ["Kathleen E Sullivan", 2015, "Genetic sharing and heritability of paediatric age of onset autoimmune diseases"], ["Struan FA Grant", 2015, "Genetic sharing and heritability of paediatric age of onset autoimmune diseases"], ["Marilynn Punaro", 2015, "Genetic sharing and heritability of paediatric age of onset autoimmune diseases"], ["Jane E Munro", 2015, "Genetic sharing and heritability of paediatric age of onset autoimmune diseases"], ["Carol Wise", 2015, "Genetic sharing and heritability of paediatric age of onset autoimmune diseases"], ["Erasmo Miele", 2015, "Genetic sharing and heritability of paediatric age of onset autoimmune diseases"], ["S Melkorka Maggadottir", 2015, "Genetic sharing and heritability of paediatric age of onset autoimmune diseases"], ["Haijun Qui", 2015, "Genetic sharing and heritability of paediatric age of onset autoimmune diseases"], ["Patrick MA Sleiman", 2015, "Genetic sharing and heritability of paediatric age of onset autoimmune diseases"], ["Debra J Abrams", 2015, "Genetic sharing and heritability of paediatric age of onset autoimmune diseases"], ["\u00d8ystein F\u00f8rre", 2015, "Genetic sharing and heritability of paediatric age of onset autoimmune diseases"], ["Hongzhe Li", 2015, "Genetic sharing and heritability of paediatric age of onset autoimmune diseases"], ["Berit Flat\u00f8", 2015, "Genetic sharing and heritability of paediatric age of onset autoimmune diseases"], ["Annamaria Staiano", 2015, "Genetic sharing and heritability of paediatric age of onset autoimmune diseases"], ["Julie Kobie", 2015, "Genetic sharing and heritability of paediatric age of onset autoimmune diseases"], ["Brendan J Keating", 2015, "Genetic sharing and heritability of paediatric age of onset autoimmune diseases"], ["Anna Latiano", 2015, "Genetic sharing and heritability of paediatric age of onset autoimmune diseases"], ["John J Connolly", 2015, "Genetic sharing and heritability of paediatric age of onset autoimmune diseases"], ["Mara L Becker", 2015, "Genetic sharing and heritability of paediatric age of onset autoimmune diseases"], ["James Snyder", 2015, "Genetic sharing and heritability of paediatric age of onset autoimmune diseases"], ["Constantin Polychronakos", 2015, "Genetic sharing and heritability of paediatric age of onset autoimmune diseases"], ["Marina Bakay", 2015, "Genetic sharing and heritability of paediatric age of onset autoimmune diseases"], ["Richard K Russell", 2015, "Genetic sharing and heritability of paediatric age of onset autoimmune diseases"], ["Dong Li", 2015, "Genetic sharing and heritability of paediatric age of onset autoimmune diseases"], ["Yiran Guo", 2015, "Genetic sharing and heritability of paediatric age of onset autoimmune diseases"], ["Susan D Thompson", 2015, "Genetic sharing and heritability of paediatric age of onset autoimmune diseases"], ["Charlotte Cunningham-Rundles", 2015, "Genetic sharing and heritability of paediatric age of onset autoimmune diseases"], ["Edward M Behrens", 2015, "Genetic sharing and heritability of paediatric age of onset autoimmune diseases"], ["Jin Li", 2015, "Genetic sharing and heritability of paediatric age of onset autoimmune diseases"], ["Christopher J Cardinale", 2015, "Genetic sharing and heritability of paediatric age of onset autoimmune diseases"], ["Terri H Finkel", 2015, "Genetic sharing and heritability of paediatric age of onset autoimmune diseases"], ["Rosetta M Chiavacci", 2015, "Genetic sharing and heritability of paediatric age of onset autoimmune diseases"], ["Frank D Mentch", 2015, "Genetic sharing and heritability of paediatric age of onset autoimmune diseases"], ["Kelly A Thomas", 2015, "Genetic sharing and heritability of paediatric age of onset autoimmune diseases"], ["Laura Steel", 2015, "Genetic sharing and heritability of paediatric age of onset autoimmune diseases"], ["Cecilia E Kim", 2015, "Genetic sharing and heritability of paediatric age of onset autoimmune diseases"], ["Eline T Luning Prak", 2015, "Genetic sharing and heritability of paediatric age of onset autoimmune diseases"], ["Peter Lakatos", 2015, "The Interaction Between NOD2 and Smoking Is Specific to the 1007fs SNP of the NOD2 Gene in Crohn's Disease: A Systematic Review and Meta-analysis: 1979"], ["Herman W Barkema", 2015, "The Interaction Between NOD2 and Smoking Is Specific to the 1007fs SNP of the NOD2 Gene in Crohn's Disease: A Systematic Review and Meta-analysis: 1979"], ["Cheryl Barnabe", 2015, "The Interaction Between NOD2 and Smoking Is Specific to the 1007fs SNP of the NOD2 Gene in Crohn's Disease: A Systematic Review and Meta-analysis: 1979"], ["Ellen Kuenzig", 2015, "The Interaction Between NOD2 and Smoking Is Specific to the 1007fs SNP of the NOD2 Gene in Crohn's Disease: A Systematic Review and Meta-analysis: 1979"], ["Cynthia Seow", 2015, "The Interaction Between NOD2 and Smoking Is Specific to the 1007fs SNP of the NOD2 Gene in Crohn's Disease: A Systematic Review and Meta-analysis: 1979"], ["Subrata Ghosh", 2015, "The Interaction Between NOD2 and Smoking Is Specific to the 1007fs SNP of the NOD2 Gene in Crohn's Disease: A Systematic Review and Meta-analysis: 1979"], ["Levinus A Dieleman", 2015, "Age at Diagnosis of Crohn's Disease May Explain NOD2-Smoking Interactions: 1975"], ["Richard Fedorak", 2015, "Age at Diagnosis of Crohn's Disease May Explain NOD2-Smoking Interactions: 1975"], ["Nicole Selenko-Gebauer", 2015, "Medication Adherence in Inflammatory Bowel Disease in the Global ALIGN Study: Impact of Concerns and Perceived Necessity of Immunosuppressants, 5-Aminosalicylates, and Tumor \u2026"], ["Pierre Michetti", 2015, "Medication Adherence in Inflammatory Bowel Disease in the Global ALIGN Study: Impact of Concerns and Perceived Necessity of Immunosuppressants, 5-Aminosalicylates, and Tumor \u2026"], ["Joel Petersson", 2015, "Medication Adherence in Inflammatory Bowel Disease in the Global ALIGN Study: Impact of Concerns and Perceived Necessity of Immunosuppressants, 5-Aminosalicylates, and Tumor \u2026"], ["Ahmed Omar", 2015, "Abdominal X-Rays Can Reliably Detect the Majority of CT Positive Sacroiliitis in an IBD Cohort: Abstract Number: 1724"], ["W Bemelman", 2015, "Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target"], ["G d'Haens", 2015, "Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target"], ["I Dotan", 2015, "Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target"], ["M Dubinsky", 2015, "Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target"], ["G Bouguen", 2015, "Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target"], ["RH Riddell", 2015, "Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target"], ["I Ord\u00e1s", 2015, "Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target"], ["PL Lakatos", 2015, "Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target"], ["G Fiorino", 2015, "Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target"], ["S Krishnareddy", 2015, "Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target"], ["J Stoker", 2015, "Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target"], ["S Winer", 2015, "Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target"], ["TB Murdoch", 2015, "Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target"], ["G Van Assche", 2015, "Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target"], ["S O'donnell", 2015, "Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target"], ["J Ruel", 2015, "Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target"], ["Edward Vincent Loftus Jr", 2015, "Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target"], ["P Munkholm", 2015, "Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target"], ["BE Sands", 2015, "Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target"], ["DT Rubin", 2015, "Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target"], ["P Marteau", 2015, "Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target"], ["J-F Colombel", 2015, "Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target"], ["RV Bryant", 2015, "Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target"], ["M Samaan", 2015, "Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target"], ["Charlly Kao", 2015, "Meta-analysis of shared genetic architecture across ten pediatric autoimmune diseases"], ["Diana Chang", 2015, "Meta-analysis of shared genetic architecture across ten pediatric autoimmune diseases"], ["Marylyn D Richie", 2015, "Meta-analysis of shared genetic architecture across ten pediatric autoimmune diseases"], ["Feng Gao", 2015, "Meta-analysis of shared genetic architecture across ten pediatric autoimmune diseases"], ["Haijun Qiu", 2015, "Meta-analysis of shared genetic architecture across ten pediatric autoimmune diseases"], ["Alon Keinan", 2015, "Meta-analysis of shared genetic architecture across ten pediatric autoimmune diseases"], ["Carol A Wise", 2015, "Meta-analysis of shared genetic architecture across ten pediatric autoimmune diseases"], ["Cuiping Hou", 2015, "Meta-analysis of shared genetic architecture across ten pediatric autoimmune diseases"], ["Amreen Dinani", 2015, "Predictors of outcome in ulcerative colitis"], ["Conghui H Guo", 2015, "Defects in nicotinamide-adenine dinucleotide phosphate oxidase genes NOX1 and DUOX2 in very early onset inflammatory bowel disease"], ["Cornelia Thoeni", 2015, "Defects in nicotinamide-adenine dinucleotide phosphate oxidase genes NOX1 and DUOX2 in very early onset inflammatory bowel disease"], ["Luis A Alvarez", 2015, "Defects in nicotinamide-adenine dinucleotide phosphate oxidase genes NOX1 and DUOX2 in very early onset inflammatory bowel disease"], ["Scott B Snapper", 2015, "Defects in nicotinamide-adenine dinucleotide phosphate oxidase genes NOX1 and DUOX2 in very early onset inflammatory bowel disease"], ["Ulla G Knaus", 2015, "Defects in nicotinamide-adenine dinucleotide phosphate oxidase genes NOX1 and DUOX2 in very early onset inflammatory bowel disease"], ["James H Doroshow", 2015, "Defects in nicotinamide-adenine dinucleotide phosphate oxidase genes NOX1 and DUOX2 in very early onset inflammatory bowel disease"], ["Holm H Uhlig", 2015, "Defects in nicotinamide-adenine dinucleotide phosphate oxidase genes NOX1 and DUOX2 in very early onset inflammatory bowel disease"], ["Patti Hayes", 2015, "Defects in nicotinamide-adenine dinucleotide phosphate oxidase genes NOX1 and DUOX2 in very early onset inflammatory bowel disease"], ["Gabriella Aviello", 2015, "Defects in nicotinamide-adenine dinucleotide phosphate oxidase genes NOX1 and DUOX2 in very early onset inflammatory bowel disease"], ["Lidija Kovacic", 2015, "Defects in nicotinamide-adenine dinucleotide phosphate oxidase genes NOX1 and DUOX2 in very early onset inflammatory bowel disease"], ["Kim O\u2019Neill", 2015, "Defects in nicotinamide-adenine dinucleotide phosphate oxidase genes NOX1 and DUOX2 in very early onset inflammatory bowel disease"], ["Billy Bourke", 2015, "Defects in nicotinamide-adenine dinucleotide phosphate oxidase genes NOX1 and DUOX2 in very early onset inflammatory bowel disease"], ["Sandeep Dhillon", 2015, "Defects in nicotinamide-adenine dinucleotide phosphate oxidase genes NOX1 and DUOX2 in very early onset inflammatory bowel disease"], ["Abdul Elkadri", 2015, "Defects in nicotinamide-adenine dinucleotide phosphate oxidase genes NOX1 and DUOX2 in very early onset inflammatory bowel disease"], ["John H Brumell", 2015, "Defects in nicotinamide-adenine dinucleotide phosphate oxidase genes NOX1 and DUOX2 in very early onset inflammatory bowel disease"], ["Sanjay K Murthy", 2015, "Extent of early clinical response to infliximab predicts long-term treatment success in active ulcerative colitis"], ["Reka Thanabalan", 2015, "Vaccination in inflammatory bowel disease patients: attitudes, knowledge, and uptake"], ["Gurtej Malhi", 2015, "Vaccination in inflammatory bowel disease patients: attitudes, knowledge, and uptake"], ["Pablo E Serrano", 2015, "Progression and management of duodenal neoplasia in familial adenomatous polyposis: a cohort study"], ["Dowan Kim", 2015, "Progression and management of duodenal neoplasia in familial adenomatous polyposis: a cohort study"], ["Aaron Pollett", 2015, "Progression and management of duodenal neoplasia in familial adenomatous polyposis: a cohort study"], ["Terri C Berk", 2015, "Progression and management of duodenal neoplasia in familial adenomatous polyposis: a cohort study"], ["Robert C Grant", 2015, "Progression and management of duodenal neoplasia in familial adenomatous polyposis: a cohort study"], ["Gary R May", 2015, "Progression and management of duodenal neoplasia in familial adenomatous polyposis: a cohort study"], ["Steven Gallinger", 2015, "Progression and management of duodenal neoplasia in familial adenomatous polyposis: a cohort study"], ["Paul Kortan", 2015, "Progression and management of duodenal neoplasia in familial adenomatous polyposis: a cohort study"], ["Hassan Al-Ali", 2015, "Progression and management of duodenal neoplasia in familial adenomatous polyposis: a cohort study"], ["Siddharth P Shah", 2015, "Su1330 Seasonal Variations Among Hospitalizations Related to Inflammatory Bowel Disease in United States"], ["Raxitkumar Jinjuvadia", 2015, "Su1330 Seasonal Variations Among Hospitalizations Related to Inflammatory Bowel Disease in United States"], ["Jason Schairer", 2015, "Su1330 Seasonal Variations Among Hospitalizations Related to Inflammatory Bowel Disease in United States"], ["Adrienne Lenhart", 2015, "Su1330 Seasonal Variations Among Hospitalizations Related to Inflammatory Bowel Disease in United States"], ["Suthat Liangpunsakul", 2015, "Su1330 Seasonal Variations Among Hospitalizations Related to Inflammatory Bowel Disease in United States"], ["Tae Hart", 2015, "Tu1264 Intolerance of Uncertainty and Quality of Life in Patients With Ulcerative Colitis"], ["Anitha Kumaaravel", 2015, "Tu1264 Intolerance of Uncertainty and Quality of Life in Patients With Ulcerative Colitis"], ["Elizabeth Kmiotek", 2015, "Tu1264 Intolerance of Uncertainty and Quality of Life in Patients With Ulcerative Colitis"], ["Chantal Li", 2015, "Tu1264 Intolerance of Uncertainty and Quality of Life in Patients With Ulcerative Colitis"], ["Robert G Maunder", 2015, "Tu1264 Intolerance of Uncertainty and Quality of Life in Patients With Ulcerative Colitis"], ["Sarah O'Donnell", 2015, "Su1276 Use of Anti-TNF Therapy in Patients With Crohn's Disease Complicated by an Abdominal Phlegmon"], ["Tanya P Chawla", 2015, "Su1276 Use of Anti-TNF Therapy in Patients With Crohn's Disease Complicated by an Abdominal Phlegmon"], ["Harden Huang", 2015, "Su1269 Preoperative Anti TNF \u03b1 Therapy in Ulcerative Colitis Patients Is Not Associated With an Increased Risk of Post Operative Ileal Pouch-Anal Anastomosis (IPAA) Leaks and \u2026"], ["Brenda I O'Connor", 2015, "Su1269 Preoperative Anti TNF \u03b1 Therapy in Ulcerative Colitis Patients Is Not Associated With an Increased Risk of Post Operative Ileal Pouch-Anal Anastomosis (IPAA) Leaks and \u2026"], ["Salah A Metwaly", 2015, "Su1269 Preoperative Anti TNF \u03b1 Therapy in Ulcerative Colitis Patients Is Not Associated With an Increased Risk of Post Operative Ileal Pouch-Anal Anastomosis (IPAA) Leaks and \u2026"], ["Richard N Fedorak", 2015, "Su1323 Patients With Crohn's Disease Who Never Smoke Are More Likely to Carry NOD2 Variants: A Case-Only NOD2-Smoking Interaction Study"], ["Cynthia H Seow", 2015, "Su1323 Patients With Crohn's Disease Who Never Smoke Are More Likely to Carry NOD2 Variants: A Case-Only NOD2-Smoking Interaction Study"], ["Wallace K MacNaughton", 2015, "Su1323 Patients With Crohn's Disease Who Never Smoke Are More Likely to Carry NOD2 Variants: A Case-Only NOD2-Smoking Interaction Study"], ["Paul L Beck", 2015, "Su1323 Patients With Crohn's Disease Who Never Smoke Are More Likely to Carry NOD2 Variants: A Case-Only NOD2-Smoking Interaction Study"], ["Jon Meddings", 2015, "Determinants of intestinal permeability in healthy first-degree relatives of individuals with Crohn's disease"], ["Gediminas Kiudelis", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["Stephen Leslie", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["Jonah Essers", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["Philip Fleshner", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["Chris Hawkey", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["Jimmy Z Liu", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["D Mauro", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["Natalie J Prescott", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["Aylwin Ng", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["Joshua C Bis", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["Sarah L Spain", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["Angela Chew", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["Tom H Karlsen", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["Tim Florin", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["Leila Amininejad", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["Ur\u00f5s Potocnik", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["Elena S Gusareva", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["Susanna Nikolaus", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["Eva Ellinghaus", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["Matija Hedl", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["Jeremy D Sanderson", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["Ailsa Hart", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["Mitja Mitrovic", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["Karin Fransen", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["Nicholas K Hayward", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["Martine De Vos", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["D Renata", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["Jurgita Sventoraityte", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["Ingo Thomsen", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["Eric E Schadt", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["Marcis Leja", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["Theodore M Bayless", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["Anne Phillips", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["Tobias Balschun", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["Laimas Jonaitis", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["Christian Gieger", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["Goda Denapiene", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["Christopher G Mathew", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["Jorge R Oksenberg", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["Soumya Raychaudhuri", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["Todd Green", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["Ariella Cohain", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["Marcin Imielinski", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["Xinli Hu", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["Jurgita Skieceviciene", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["Miquel Sans", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["Florian Rieder", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["Eleonora A Festen", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["Stephen L Hauser", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["Kathy L Devaney", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["David Ellinghaus", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["Paolo Lionetti", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["Mark Seielstad", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["Cyriel Y Ponsioen", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["William Newman", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["Dermot Mallon", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["Orazio Palmieri", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["Craig Mowat", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["Dirk De Jong", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["Markus N\u00f6then", 2015, "High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis"], ["Oystein F\u00f8rre", 2015, "Genetic sharing and heritability of paediatric age of onset autoimmune diseases"], ["Li Hongzhe", 2015, "Genetic sharing and heritability of paediatric age of onset autoimmune diseases"], ["R Yun", 2015, "Genetic sharing and heritability of paediatric age of onset autoimmune diseases"], ["Li Jin", 2015, "Genetic sharing and heritability of paediatric age of onset autoimmune diseases"], ["Li Dong", 2015, "Genetic sharing and heritability of paediatric age of onset autoimmune diseases"], ["Charlotte Cunningham Rundles", 2015, "Genetic sharing and heritability of paediatric age of onset autoimmune diseases"], ["Patrick Sleiman", 2015, "Genetic sharing and heritability of paediatric age of onset autoimmune diseases"], ["MDCM Kenneth Croitoru", 2015, "Predictors of Outcome in Ulcerative Colitis"], ["Travis B Murdoch", 2015, "Biomarkers as potential treatment targets in inflammatory bowel disease: a systematic review"]]}